<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7481143\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="abstract Abstract Urgent treatments, in any modality, to fight SARS-CoV-2" exact="infections" post="are desired by society in general, by health professionals,"/>
  <result pre="The world is facing a huge challenge in the coronavirus" exact="disease" post="(COVID-19) pandemic: How to fight an enemy without weapons"/>
  <result pre="without weapons in terms of therapy? Unfortunately, even before the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) worldwide spread, there"/>
  <result pre="weapons in terms of therapy? Unfortunately, even before the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) worldwide spread, there were"/>
  <result pre="in terms of therapy? Unfortunately, even before the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) worldwide spread, there were no"/>
  <result pre="terms of therapy? Unfortunately, even before the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) worldwide spread, there were no clinical"/>
  <result pre="and molecular modelling to verify possible interactions between the selected" exact="viral" post="targets and the drug structures present in their molecular"/>
  <result pre="to highlight that, if one compound is active against a" exact="viral" post="disease such as COVID-19, there can be a mechanism"/>
  <result pre="highlight that, if one compound is active against a viral" exact="disease" post="such as COVID-19, there can be a mechanism of"/>
  <result pre="and Î²CoV are considered human pathogens (HCoVs) usually related to" exact="respiratory" post="illness and gastroenteritis. In the past few years, HCoVs"/>
  <result pre="capacity, high levels of nucleotide substitutions, their efficiency in causing" exact="infection" post="in new hosts and interspecies transmission.12 HCoVs, such as"/>
  <result pre="draw attention until November 2002, when the coronavirus of severe" exact="acute" post="respiratory syndrome (SARS-CoV) emerged in Guangdong province, China.13 Since"/>
  <result pre="attention until November 2002, when the coronavirus of severe acute" exact="respiratory" post="syndrome (SARS-CoV) emerged in Guangdong province, China.13 Since then,"/>
  <result pre="until November 2002, when the coronavirus of severe acute respiratory" exact="syndrome" post="(SARS-CoV) emerged in Guangdong province, China.13 Since then, the"/>
  <result pre="Middle Eastern countries.14 The virus was named the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) and infected 2494 individuals and caused"/>
  <result pre="Eastern countries.14 The virus was named the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) and infected 2494 individuals and caused 858"/>
  <result pre="named SARS-CoV-2.17 SARS-CoV-2 is associated with an ongoing outbreak of" exact="atypical pneumonia" post="(COVID-2019). It has already affected over 8,506,107 people and"/>
  <result pre="SARS-CoV-2.17 SARS-CoV-2 is associated with an ongoing outbreak of atypical" exact="pneumonia" post="(COVID-2019). It has already affected over 8,506,107 people and"/>
  <result pre="and pp1ab, respectively. Afterwards, these polyproteins are cleaved by two" exact="viral" post="proteases, the papain-like protease (PLpro) and the 3 chymotrypsin-like"/>
  <result pre="encode structural proteins, including those related to physical structure of" exact="viral" post="particles (capsid, envelope), such as the glycoproteins spike (S),"/>
  <result pre="genome and the S, E and M proteins constitute the" exact="viral" post="envelope.23 Since the announcement of the pandemic by the"/>
  <result pre="Rhinolophus affinis bat (BatCoV RaTG13), which suggests bats act as" exact="intermediate" post="hosts for SARS-CoV-2.17 It is important to keep in"/>
  <result pre="due to human activities, including eating habits and urbanization.1 The" exact="absence of" post="caution or barriers between natural reservoirs and human society"/>
  <result pre="to the virus adaptation and human-to-human transmission through contact via" exact="respiratory" post="droplets generated when an infected person speaks, coughs or"/>
  <result pre="a different person inhales the aerosols, which depend on the" exact="viral" post="shedding for dissemination.26 The droplet reaching power varies according"/>
  <result pre="molecular biology as well as available advances and technology. SARS-CoV-2" exact="infection" post="is generally detected by reverse transcriptaseâ€&quot;polymerase chain reaction (RT-PCR)"/>
  <result pre="can direct the cell machinery to produce more viruses.33 A" exact="viral infection" post="is successful when the virus crosses the host cell"/>
  <result pre="direct the cell machinery to produce more viruses.33 A viral" exact="infection" post="is successful when the virus crosses the host cell"/>
  <result pre="fusions with the cellular membrane, a process mediated by specialized" exact="viral" post="proteins.34 In relation to SARS-CoV-2, its life cycle starts"/>
  <result pre="is largely expressed in fifteen human tissues, including ciliated bronchial" exact="epithelial" post="cells and type II pneumocytes form pulmonary alveoli, the"/>
  <result pre="in fifteen human tissues, including ciliated bronchial epithelial cells and" exact="type II" post="pneumocytes form pulmonary alveoli, the main location of lesions"/>
  <result pre="including ciliated bronchial epithelial cells and type II pneumocytes form" exact="pulmonary" post="alveoli, the main location of lesions caused by SARS-CoV-2.36,"/>
  <result pre="releases the RNA into the cytoplasm to be translated into" exact="viral" post="replicase polyproteins including proteases (3CLpro and PLpro), which cleavage"/>
  <result pre="exocytosis. The structures of some promising therapeutic targets available on" exact="Protein" post="Data Bank are: (a) SARS-CoV-2 Spike glycoprotein (PDB ID"/>
  <result pre="alteration occurs in protein S allowing the fusion between the" exact="viral" post="envelope and the host cell membrane via endosomal. Then,"/>
  <result pre="releases the RNA into the cytoplasm to be translated into" exact="viral" post="replicase polyproteins pp1a and pp1ab, which are processed by"/>
  <result pre="mRNAs are translated and transcribed producing structural and accessory proteins." exact="Viral" post="proteins and RNA genomic are put together in virions"/>
  <result pre="symptoms and 3â€¯days after lowering of fever and improvement of" exact="respiratory" post="symptoms.41 There are many unanswered questions such as the"/>
  <result pre="questions such as the duration of potential immunity of both" exact="symptomatic" post="and asymptomatic individuals when infected with SARS-CoV-2.31 It is"/>
  <result pre="SARS-CoV-2.31 It is noteworthy that efficient strategies to fight the" exact="disease" post="should not depend on the symptoms of patients, once"/>
  <result pre="the transmission to other residents. Thus, control strategies focused on" exact="symptomatic" post="residents were not sufficient to prevent transmission once SARS-CoV-2"/>
  <result pre="of Granulocyte-colony stimulating factor (GCSF), protein induced by interferon gamma," exact="Monocyte" post="Chemoattractant Protein-1 (MCP-1), macrophages inflammatory protein 1Î± and TNF-Î±"/>
  <result pre="of COVID-19 include elderly individuals (specially above 65â€¯years of age)," exact="cardiovascular" post="issues, cerebrovascular, chronic pulmonary diseases, immunocompromising, renal problems, hepatic"/>
  <result pre="elderly individuals (specially above 65â€¯years of age), cardiovascular issues, cerebrovascular," exact="chronic" post="pulmonary diseases, immunocompromising, renal problems, hepatic disease, hypertension, diabetes"/>
  <result pre="individuals (specially above 65â€¯years of age), cardiovascular issues, cerebrovascular, chronic" exact="pulmonary" post="diseases, immunocompromising, renal problems, hepatic disease, hypertension, diabetes and"/>
  <result pre="age), cardiovascular issues, cerebrovascular, chronic pulmonary diseases, immunocompromising, renal problems," exact="hepatic disease," post="hypertension, diabetes and obesity.44, 45, 46, 47, 48, 49"/>
  <result pre="cerebrovascular, chronic pulmonary diseases, immunocompromising, renal problems, hepatic disease, hypertension," exact="diabetes" post="and obesity.44, 45, 46, 47, 48, 49 There is"/>
  <result pre="necessary to explore whether these medicines inhibit or trigger the" exact="viral" post="entry into the cells of an infected host.51 A"/>
  <result pre="effects of SARS-CoV-2 for the different organs affected by the" exact="disease" post="has also been object of investigation, such as gut-lung"/>
  <result pre="crosstalk.55 Data from research conducted thus far indicate that the" exact="infection" post="caused by SARS-CoV-2 is not only capable of causing"/>
  <result pre="system.44, 56, 57 Patients with the extreme form of the" exact="disease" post="frequently manifest lymphopenia,30, 57 hepatic insufficiency58 and viral sepsis"/>
  <result pre="of the disease frequently manifest lymphopenia,30, 57 hepatic insufficiency58 and" exact="viral" post="sepsis diagnostic,51 whose complications can be related to the"/>
  <result pre="death of such patients is due to multiple organ insufficiency," exact="acute" post="respiratory distress syndrome (ARDS), cardiac insufficiency, arrhythmia and renal"/>
  <result pre="of such patients is due to multiple organ insufficiency, acute" exact="respiratory" post="distress syndrome (ARDS), cardiac insufficiency, arrhythmia and renal insufficiency.56,"/>
  <result pre="patients is due to multiple organ insufficiency, acute respiratory distress" exact="syndrome" post="(ARDS), cardiac insufficiency, arrhythmia and renal insufficiency.56, 59 Therefore,"/>
  <result pre="multiple organ insufficiency, acute respiratory distress syndrome (ARDS), cardiac insufficiency," exact="arrhythmia" post="and renal insufficiency.56, 59 Therefore, great attention is necessary"/>
  <result pre="can have side effects on organs initially unrelated to the" exact="respiratory" post="system, but that may be susceptible to a systemic"/>
  <result pre="the respiratory system, but that may be susceptible to a" exact="systemic" post="compromise prompted by the virus once the treatment has"/>
  <result pre="in the host, which are associated to the severity of" exact="pulmonary" post="pathology and might lead to the development of acute"/>
  <result pre="of pulmonary pathology and might lead to the development of" exact="acute" post="respiratory distress syndrome (ARDS) or death.57 The incidence of"/>
  <result pre="pulmonary pathology and might lead to the development of acute" exact="respiratory" post="distress syndrome (ARDS) or death.57 The incidence of the"/>
  <result pre="and might lead to the development of acute respiratory distress" exact="syndrome" post="(ARDS) or death.57 The incidence of the extreme form"/>
  <result pre="or death.57 The incidence of the extreme form of the" exact="infection" post="is associated with cytokine storm syndrome, characterized by high"/>
  <result pre="response by the immune system can develop long-term fibrosis and" exact="pulmonary" post="damages that might culminate in functional injuries to these"/>
  <result pre="(1) CoVs proteins or functional enzymes that are essential for" exact="viral" post="replication; (2) structural proteins of the virus that prevent"/>
  <result pre="receptors in human cells or its assembly process; (3) some" exact="viral" post="factor that restores the hostâ€™s inherent immunity and; (4)"/>
  <result pre="proteins and enzymes that participate actively in the process of" exact="viral" post="replication are the most investigated targets for the development"/>
  <result pre="spike (S) glycoprotein is a transmembrane protein of approximately 180â€&quot;200â€¯kDa" exact="type I" post="whose N-terminal turns to the exterior of the virus"/>
  <result pre="to subunit S1. Next, the subunit S2 allows fusion of" exact="viral" post="and cellular membranes, which enables entry in the cell"/>
  <result pre="which enables entry in the cell and the release of" exact="viral" post="RNA genome.35, 65, 66 Some investigations suggest that the"/>
  <result pre="binding affinity between S protein and ACE2 is essential for" exact="viral" post="entry, hence, ACE2 is also relevant for the development"/>
  <result pre="Hoffman et al.35 investigated how the SARS-CoV-2 S protein facilitates" exact="viral" post="entry in the target cells and how this process"/>
  <result pre="pockets of the quaternary structure of SARS-CoV-2 S glycoprotein (from" exact="Protein" post="Data Bank-PDB). Six pockets present in S glycoprotein deserve"/>
  <result pre="in the RNA transcription, translation, protein synthesis, processing and modification," exact="viral" post="replication and infection of the host. Significant functional proteins,"/>
  <result pre="transcription, translation, protein synthesis, processing and modification, viral replication and" exact="infection" post="of the host. Significant functional proteins, 3CLpro, PLpro, helicases"/>
  <result pre="known as Nsp5, cleavages several non-structural proteins of importance for" exact="viral" post="replication and the maturation of Nsps, which is essential"/>
  <result pre="molecular dynamic studies conducted by Qamar et al.77 showed that" exact="non-toxic" post="natural products formed strong bonds with SARS-CoV-2 catalytic dyad"/>
  <result pre="and nucleic acid remodelling. For CoVs, helicase is indispensable for" exact="viral" post="replication. In studies on molecular modelling, several antibacterial, antifungal"/>
  <result pre="RNA-dependent RNA polymerase (RdRp â€&quot; also nominated Nsp12) catalyses the" exact="viral" post="RNA, which performs a key role in the replication/transcription"/>
  <result pre="several SARS-CoV and MERS-CoV inhibitors, due to its importance for" exact="viral" post="control. Satisfactory results of RdRp inhibition by several ligands"/>
  <result pre="to their significant role in the synthesis and replication of" exact="viral" post="RNA.5 3CLpro is key enzyme for CoVs, also called"/>
  <result pre="Main protease (Mpro), that plays a pivotal role in mediating" exact="viral" post="replication and transcription, making it an attractive target for"/>
  <result pre="a time-dependent irreversible inhibitor of this enzyme and that a" exact="stable" post="covalent bond is formed between N3 and 3CLpro. High-throughput"/>
  <result pre="and for each medicine, the putative mechanism of action and" exact="viral" post="target will be described trying to find an understandable"/>
  <result pre="virus, after entry in the host cell, replicates fast the" exact="viral" post="genome with new virion production. The RNA replication into"/>
  <result pre="is used in the treatment of oesophageal cancer,82 stomach cancer,91" exact="breast" post="and colon cancer.92 The similarity between 5-FU and uracil"/>
  <result pre="anticancer therapy. It became, then, widely used against non-small cell" exact="lung cancer," post="pancreas, bladder and breast cancers as well.95, 96, 97In-vitro"/>
  <result pre="widely used against non-small cell lung cancer, pancreas, bladder and" exact="breast" post="cancers as well.95, 96, 97In-vitro analyses of gemcitabine hydrochloride"/>
  <result pre="under predetermined doses, GCT adverse effects are noteworthy and include" exact="myelosuppression" post="and disruption of liver functions. 5.1.3 Baricitinib In February"/>
  <result pre="GCT adverse effects are noteworthy and include myelosuppression and disruption" exact="of liver" post="functions. 5.1.3 Baricitinib In February 2017, the European Union"/>
  <result pre="(10) as second-line oral treatment for mild to severe active" exact="rheumatoid arthritis" post="in adults (Fig. 3).9 A differential feature of Baricitinib"/>
  <result pre="as second-line oral treatment for mild to severe active rheumatoid" exact="arthritis" post="in adults (Fig. 3).9 A differential feature of Baricitinib"/>
  <result pre="important mechanisms of action of baricitinib in the treatment of" exact="rheumatoid arthritis" post="is the inhibition of the IL-6 / JAK1 /"/>
  <result pre="mechanisms of action of baricitinib in the treatment of rheumatoid" exact="arthritis" post="is the inhibition of the IL-6 / JAK1 /"/>
  <result pre="entry to the cells and the intracellular assembly of new" exact="viral" post="particles (Fig. 3). Regarding these two antitumor drugs, it"/>
  <result pre="oxindole multitargeted kinase inhibitor that inhibits certain tyrosine kinases including" exact="vascular" post="endothelial growth factor receptors (VEGFR types 1 and 2),"/>
  <result pre="is highlighted that Baricitinib is not indicated for patients with" exact="neutropenia" post="or lymphopenia, once it lowers rates of neutrocytes and"/>
  <result pre="lowers rates of neutrocytes and lymphocytes, which can lead the" exact="disease" post="to progress and increase anaemia. Furthermore, treatment with Baricitinib"/>
  <result pre="and increase anaemia. Furthermore, treatment with Baricitinib can reactivate varicella-zoster," exact="herpes" post="simplex and Epstein-Barr viruses. This implicates in a conflict"/>
  <result pre="adverse effects of Baricitinib against COVID-19 to prevent aggravating the" exact="disease" post="and the mortality of patients.104 5.1.4 Galidesivir (GSV) An"/>
  <result pre="Galidesivir (GSV) (13) is a broad-spectrum antiviral drug that blocks" exact="viral" post="RNA polymerase by replacing a natural nucleotide with galidesivir"/>
  <result pre="in advanced stages of development.107 GSV was first developed against" exact="hepatitis C" post="(HCV) but first clinical trials were conducted to ensure"/>
  <result pre="to ensure its safety (in healthy individuals) and efficacy against" exact="yellow fever." post="Furthermore, GSV displayed in-vitro and in-vivo antiviral activity against"/>
  <result pre="have pointed the inactivity of GSV against SARS-CoV-2 at concentrations" exact="lower" post="than 100 mÎœ.109 The existence of antiviral activity against"/>
  <result pre="approved by the Food Drug Administration (FDA) since 2013, against" exact="chronic hepatitis C" post="infections. SBV is also combined with other antiviral drugs,"/>
  <result pre="by the Food Drug Administration (FDA) since 2013, against chronic" exact="hepatitis C" post="infections. SBV is also combined with other antiviral drugs,"/>
  <result pre="drug to act on HCV RdRp, incorporate itself into the" exact="viral" post="RNA and terminate the synthesis of the nucleotide sequence.81"/>
  <result pre="viral RNA and terminate the synthesis of the nucleotide sequence.81" exact="Structural" post="analysis of SBV revealed that its elevated potential is"/>
  <result pre="due to the presence of the 5â€²-phosphate, which terminates the" exact="primary" post="enzyme transformation monophosphate inhibitor.112 The antiviral activity has been"/>
  <result pre="for inhibiting the dengue virus,113 yellow fever,114 zika virus,115 and" exact="chikungunya" post="virus.116 Regarding SARS-CoV-2 results, in-silico evaluation of SBV indicated"/>
  <result pre="a thymidine nucleoside analogue used with specific activity against the" exact="hepatitis" post="B virus (HBV). It starts acting after phosphorylation by"/>
  <result pre="the active metabolite, Telbivudine 5â€²â€&quot;triphosphate, enabling DNA polymerase and inhibiting" exact="viral" post="replication. The hydroxyl at 3-position in the sugar Î²-L-2â€²-desoxirribose"/>
  <result pre="prompted by virtual screening to find drugs that act on" exact="viral" post="Mpro. Among other results were Ribavirin, TBV and two"/>
  <result pre="to TBV, which was verified in preclinical trials against HIV," exact="herpes" post="simplex virus (HSV), varicella-zoster virus (VZV), Epstein-Barr virus (HSV-4)"/>
  <result pre="development of promising candidates to treat cancer,123 asthma,124 inflammations and" exact="autoimmune" post="diseases,125 rheumatoid arthritis and various diseases.126 The antiviral potential"/>
  <result pre="promising candidates to treat cancer,123 asthma,124 inflammations and autoimmune diseases,125" exact="rheumatoid arthritis" post="and various diseases.126 The antiviral potential of purine derivatives"/>
  <result pre="candidates to treat cancer,123 asthma,124 inflammations and autoimmune diseases,125 rheumatoid" exact="arthritis" post="and various diseases.126 The antiviral potential of purine derivatives"/>
  <result pre="broad antiviral spectrum including diverse RNA viruses such as human" exact="respiratory" post="syncytial virus (HSRV), MERS-CoV, SARS-CoV and Nipah virus.129, 130"/>
  <result pre="during replication.129 RDV therapy promising results are described for several" exact="viral" post="infections. Regarding EBOV, primary evaluation includes evidence of its"/>
  <result pre="promising results are described for several viral infections. Regarding EBOV," exact="primary" post="evaluation includes evidence of its efficacy both in-vitro (primary"/>
  <result pre="and human endothelial cells) and in-vivo (rhesus monkey) by suppressing" exact="viral" post="replication and completely protecting animals as clinical symptoms of"/>
  <result pre="replication and completely protecting animals as clinical symptoms of the" exact="disease" post="and pathophysiology markers improved.131 The safety of RDV for"/>
  <result pre="as superior to 10â€¯Î¼M. The assay was conducted on a" exact="secondary" post="cell line (HAE) and confirmed the low concentrations necessary"/>
  <result pre="cell line (HAE) and confirmed the low concentrations necessary for" exact="viral" post="inhibition with average values of 0.069â€¯Î¼M (SARS-CoV) and 0.074â€¯Î¼M"/>
  <result pre="RDV indicate improvement of lung functions, decrease of the severe" exact="pulmonary" post="form of the disease and reduction of viral loads"/>
  <result pre="lung functions, decrease of the severe pulmonary form of the" exact="disease" post="and reduction of viral loads and weight loss in"/>
  <result pre="the severe pulmonary form of the disease and reduction of" exact="viral" post="loads and weight loss in murine.134 Therefore, RDV is"/>
  <result pre="old, had slight cough, low fever and no evidence of" exact="pneumonia" post="at day 4 of the disease. When the clinical"/>
  <result pre="study, such as the small size of the cohort, the" exact="short" post="duration of follow-up and the lack of information on"/>
  <result pre="trial. Intravenous infusions of 3â€&quot;225â€¯mg were well-tolerated without any evidence" exact="of liver" post="or kidney toxicity. RDV demonstrated linear pharmacokinetics within the"/>
  <result pre="Herpesvirus and is also indicated in the treatment of cytomegalovirus" exact="infections" post="related to Acquired Immunodeficiency Syndrome (AIDS).138 GCV is converted"/>
  <result pre="also indicated in the treatment of cytomegalovirus infections related to" exact="Acquired Immunodeficiency Syndrome" post="(AIDS).138 GCV is converted into ganciclovir triphosphate by cellular"/>
  <result pre="indicated in the treatment of cytomegalovirus infections related to Acquired" exact="Immunodeficiency Syndrome" post="(AIDS).138 GCV is converted into ganciclovir triphosphate by cellular"/>
  <result pre="in the treatment of cytomegalovirus infections related to Acquired Immunodeficiency" exact="Syndrome" post="(AIDS).138 GCV is converted into ganciclovir triphosphate by cellular"/>
  <result pre="ganciclovir triphosphate by cellular kinase, which inhibits dGTP and disrupts" exact="viral" post="DNA synthesis due to substitution of various adenosine bases"/>
  <result pre="drug due to its high binding affinity to two well-established" exact="viral" post="targets. The first target was PLpro, indispensable enzyme in"/>
  <result pre="viral targets. The first target was PLpro, indispensable enzyme in" exact="viral" post="replication; the second, RdRp, conserved Nsp12 in coronavirus, which"/>
  <result pre="strand, it causes premature termination of DNA transcription and prevents" exact="viral" post="replication.145, 146 Modelling and docking studies evaluated the antiviral"/>
  <result pre="to SARS-CoV-RdRp, which can disrupt this polymerase and terminate the" exact="viral" post="infection.7 However, in-vitro tests showed that TFV lacks apparent"/>
  <result pre="assume two isometric forms, 1,2,3-triazole and 1,2,4-triazole. The former is" exact="stable" post="under acid and basic conditions and becomes more reactive"/>
  <result pre="range of pharmacological activities related to several viruses, for instance:" exact="herpes" post="simplex virus, human immunodeficiency (HVI-1), influenza, respiratory syncytial (RSV)"/>
  <result pre="related to several viruses, for instance: herpes simplex virus, human" exact="immunodeficiency" post="(HVI-1), influenza, respiratory syncytial (RSV) and hepatitis C.148, 155"/>
  <result pre="viruses, for instance: herpes simplex virus, human immunodeficiency (HVI-1), influenza," exact="respiratory" post="syncytial (RSV) and hepatitis C.148, 155 The drug was"/>
  <result pre="simplex virus, human immunodeficiency (HVI-1), influenza, respiratory syncytial (RSV) and" exact="hepatitis" post="C.148, 155 The drug was initially used in 1980"/>
  <result pre="dehydrogenase, necessary in the synthesis of guanosine triphosphate, which prevents" exact="viral" post="DNA and, mainly, RNA replication. The necessary concentration for"/>
  <result pre="isolate hCoV-EMC/2012 replication in Vero and LLC-MK2 cells. IFN-Î±2b displayed" exact="complete" post="cytopathogenic effect (CPE) at 1000â€…U/ml and above, whereas ribavirin"/>
  <result pre="cytopathogenic effect (CPE) at 1000â€…U/ml and above, whereas ribavirin presented" exact="complete" post="CPE at 200â€¯Î¼g/ml and above. The IC50 of IFN-Î±2b"/>
  <result pre="conducted. IFN-Î±2b, at the maximum concentration tested (2000 U/ml), reduced" exact="infectious" post="titers by 3.97-log. On the other hand, ribavirin treatment,"/>
  <result pre="the other hand, ribavirin treatment, at 200â€¯Î¼g/ml or higher, reduced" exact="infectious" post="virus below the detection threshold of 13.7 TCID50/ml. Next,"/>
  <result pre="a decrease in CPE was noted. For Vero cells, the" exact="absence of" post="CPE was verified at and above 125â€…U/ml IFN-Î±2b and"/>
  <result pre="with nCoV-2019BetaCoV/Wuhan / WIV04 / 2019 at a Multiplicity of" exact="Infection" post="(MOI) of 0,05 for different concentrations of the drugs."/>
  <result pre="showed that high concentrations of ribavirin were necessary to reduce" exact="viral infection," post="with EC50â€¯=â€¯109,50â€¯Î¼M and CC50â€¯&amp;gt;â€¯400â€¯Î¼M. A docking study by Elfiky160"/>
  <result pre="and phosphorylation.162 FPV therapeutic targets are RdRp enzymes, necessary in" exact="viral" post="transcription and replication, and its inhibition blocks synthesis of"/>
  <result pre="viral transcription and replication, and its inhibition blocks synthesis of" exact="viral" post="RNA for a spectrum of viruses, including human coronavirus."/>
  <result pre="SARS-CoV-2.107 A prospective randomized, controlled, open-label multicentre trial involving 236" exact="adult" post="patients with COVID-19 was conducted to compare FPV (therapy"/>
  <result pre="under FPV therapy responded better to the progression of the" exact="disease" post="with accentuated viral depuration. Also, the incidence of nausea"/>
  <result pre="responded better to the progression of the disease with accentuated" exact="viral" post="depuration. Also, the incidence of nausea and vomit was"/>
  <result pre="evaluated but no clear antiviral effect was noted for doses" exact="lower" post="than 100â€¯Î¼M.109 Albeit its relative safety and efficacy, information"/>
  <result pre="outcomes to lopinavir/ritonavir treatment, like lesser incidence of death and" exact="acute" post="respiratory syndrome, decreasing viral load and increased peripheral lymphocyte"/>
  <result pre="to lopinavir/ritonavir treatment, like lesser incidence of death and acute" exact="respiratory" post="syndrome, decreasing viral load and increased peripheral lymphocyte numbers."/>
  <result pre="like lesser incidence of death and acute respiratory syndrome, decreasing" exact="viral" post="load and increased peripheral lymphocyte numbers. A different study"/>
  <result pre="death and acute respiratory syndrome, decreasing viral load and increased" exact="peripheral" post="lymphocyte numbers. A different study conducted by Chan et"/>
  <result pre="achieved better clinical results than the control group, such as" exact="limited" post="weight loss, stabilization of temperature, little pulmonary infiltration and"/>
  <result pre="group, such as limited weight loss, stabilization of temperature, little" exact="pulmonary" post="infiltration and smaller viral load. The outcomes are corroborated"/>
  <result pre="weight loss, stabilization of temperature, little pulmonary infiltration and smaller" exact="viral" post="load. The outcomes are corroborated by a Korean case"/>
  <result pre="(lopinavir 400â€¯mg/ritonavir 10â€¯mg 2*day), ribavirin and IFN-2a.171 The patient displayed" exact="absence of" post="fever and MERS-CoV at day 9 of treatment, in"/>
  <result pre="fever and MERS-CoV at day 9 of treatment, in a" exact="respiratory" post="sample, achieving full recovery. A recent randomized clinical assay"/>
  <result pre="was conducted in the city of Wuhan, China, with 199" exact="adult" post="patients infected with SARS-CoV-2, saturation inferior to 94% and"/>
  <result pre="infected with SARS-CoV-2, saturation inferior to 94% and ratio of" exact="partial" post="pressure arterial oxygen and fraction of inspired oxygen inferior"/>
  <result pre="LPV/RTV and 25% standard treatment) and the percentages of detectable" exact="viral" post="RNA and time of the treatment were similar in"/>
  <result pre="time of the treatment were similar in both groups. The" exact="total" post="time of treatment was one day shorter for LPV/RTV."/>
  <result pre="noteworthy that treatments began at a late stage of the" exact="disease" post="and a relatively high concentration of lopinavir was used"/>
  <result pre="a relatively high concentration of lopinavir was used to inhibit" exact="viral" post="replication.167, 172 Different researches also focused on the administration"/>
  <result pre="better outcomes than the treatment with LPV/RTV alone. The 127" exact="adult" post="patients were randomly divided into two groups: the combination"/>
  <result pre="for 14â€¯days. The treatment that combined the three drugs suppressed" exact="viral" post="loads in all clinical samples (nasopharyngeal, saliva from the"/>
  <result pre="faeces) after 8â€¯days of treatment whereas the control group suppressed" exact="viral" post="load after 12â€¯days of treatment in average. The triple"/>
  <result pre="built by taking PDB:4MDS 3CLpro as template) and papain like" exact="viral" post="protease (PLVP), suggest that effects of Kaletra are related"/>
  <result pre="help new virions to exit the cell and prevents intercellular" exact="viral" post="transmission. The virions remain on the surface of infected"/>
  <result pre="remain on the surface of infected cells, trapped in the" exact="respiratory" post="secretion. Then, oseltamivir disrupts viral dissemination in the respiratory"/>
  <result pre="infected cells, trapped in the respiratory secretion. Then, oseltamivir disrupts" exact="viral" post="dissemination in the respiratory system and reduces the time"/>
  <result pre="the respiratory secretion. Then, oseltamivir disrupts viral dissemination in the" exact="respiratory" post="system and reduces the time of infection.144, 175 Because"/>
  <result pre="with oseltamivir. However, the study presented several limitations, including the" exact="absence of" post="complete data on patients, which hinders the publication of"/>
  <result pre="However, the study presented several limitations, including the absence of" exact="complete" post="data on patients, which hinders the publication of concrete"/>
  <result pre="for combined treatment with oseltamivir and LPV/RTV, testing negative for" exact="viral infection" post="after 48â€¯h. A different study by Chen et al.140"/>
  <result pre="combined treatment with oseltamivir and LPV/RTV, testing negative for viral" exact="infection" post="after 48â€¯h. A different study by Chen et al.140"/>
  <result pre="Wuhan, China, monitored 99 patients, who were mostly 55-year-old-men, with" exact="pneumonia" post="symptoms confirmed as COVID-19. About 75% of these patients"/>
  <result pre="a highly active antiretroviral therapy (HAART) that reduces significantly the" exact="viral" post="load by increasing cell number to 200â€¯mmâˆ’3 CD4(+) lymphocytes."/>
  <result pre="is an antiretroviral drug protease inhibitor used to treat HIV" exact="infections" post="with in-vitro inhibitory concentration of 2,6â€&quot;5,3 nmol. Compared to"/>
  <result pre="which is indispensable in the processing of polyproteins precursors of" exact="viral" post="structures and prevents the formation of infectious and mature"/>
  <result pre="polyproteins precursors of viral structures and prevents the formation of" exact="infectious" post="and mature viral particles.182 The good activities reported for"/>
  <result pre="viral structures and prevents the formation of infectious and mature" exact="viral" post="particles.182 The good activities reported for this drug as"/>
  <result pre="investigations on atazanavir. Marketed drugs that could act on the" exact="viral" post="components of SARS-CoV-2 were analysed by Beck et al.185"/>
  <result pre="mouth is well-established and confirms the pharmacological activity in the" exact="short" post="term (10â€&quot;30â€¯min) at the cellular level. This capacity is"/>
  <result pre="the bond between human SARS-CoV-2 and ACE2 and reduce severe" exact="pneumonia" post="symptoms. In-silico studies using molecular docking were conducted with"/>
  <result pre="place between the critic groups, which results in a more" exact="stable" post="inhibitor complex. The hypothesis is that captopril can bind"/>
  <result pre="decades to prevent organ rejection and to treat T cell-associated" exact="autoimmune diseases" post="such as Behcetâ€™s disease, psoriatic arthritis, lupus nephritis, rheumatoid"/>
  <result pre="to treat T cell-associated autoimmune diseases such as Behcetâ€™s disease," exact="psoriatic arthritis," post="lupus nephritis, rheumatoid arthritis, systemic lupus erythematosus or interstitial"/>
  <result pre="T cell-associated autoimmune diseases such as Behcetâ€™s disease, psoriatic arthritis," exact="lupus" post="nephritis, rheumatoid arthritis, systemic lupus erythematosus or interstitial lung"/>
  <result pre="autoimmune diseases such as Behcetâ€™s disease, psoriatic arthritis, lupus nephritis," exact="rheumatoid arthritis," post="systemic lupus erythematosus or interstitial lung disease. Such drug"/>
  <result pre="such as Behcetâ€™s disease, psoriatic arthritis, lupus nephritis, rheumatoid arthritis," exact="systemic" post="lupus erythematosus or interstitial lung disease. Such drug exerts"/>
  <result pre="as Behcetâ€™s disease, psoriatic arthritis, lupus nephritis, rheumatoid arthritis, systemic" exact="lupus erythematosus" post="or interstitial lung disease. Such drug exerts its immunosuppressive"/>
  <result pre="psoriatic arthritis, lupus nephritis, rheumatoid arthritis, systemic lupus erythematosus or" exact="interstitial lung disease." post="Such drug exerts its immunosuppressive function and anti-inflammatory effects"/>
  <result pre="arthritis, lupus nephritis, rheumatoid arthritis, systemic lupus erythematosus or interstitial" exact="lung disease." post="Such drug exerts its immunosuppressive function and anti-inflammatory effects"/>
  <result pre="is thought to be mediated by the inhibition of cyclophilin-A-dependent" exact="viral" post="assembly as well as inhibition of the NF-AT pathway"/>
  <result pre="by genetic or pharmacological specific inhibition of cyclophilin-D, hindering the" exact="viral" post="replication.194, 197 As already reported, SARS-CoV and SARS-CoV-2 are"/>
  <result pre="Each drug was added to the cells prior to the" exact="virus infection." post="At 24â€¯h after the infection, the infected cells were"/>
  <result pre="scored by immunofluorescence analysis with an antibody specific for the" exact="viral" post="N protein of SARS-CoV-2. Among the 48 drugs evaluated,"/>
  <result pre="CsA to increase ACE2 shedding and, consequently, to augment SARS-CoV-2" exact="infection" post="by increment the ACE2 upregulation.200 Furthermore, the CsA has"/>
  <result pre="the CsA has serious side effects, which can cause hyperlipidaemia," exact="gingival hyperplasia," post="nausea, vomiting, abdominal pain, headache, susceptibility to infections, triggering"/>
  <result pre="can cause hyperlipidaemia, gingival hyperplasia, nausea, vomiting, abdominal pain, headache," exact="susceptibility to" post="infections, triggering of cancer development, blood pressure increase, nephrotoxicity,"/>
  <result pre="nausea, vomiting, abdominal pain, headache, susceptibility to infections, triggering of" exact="cancer" post="development, blood pressure increase, nephrotoxicity, and immune suppression. Its"/>
  <result pre="has displayed antiviral activity on an early stage of the" exact="viral" post="life cycle by inhibiting the low-pH cleavage of the"/>
  <result pre="viral life cycle by inhibiting the low-pH cleavage of the" exact="viral" post="spike protein by cathepsin L in the late endosomes"/>
  <result pre="cathepsin L in the late endosomes thereby preventing release of" exact="viral" post="RNA and replication. This compound has already shown inhibitory"/>
  <result pre="is a first line drug used as combined therapy for" exact="chronic hepatitis" post="C.207 Dasabuvir is a non-nucleoside inhibitor that binds to"/>
  <result pre="a first line drug used as combined therapy for chronic" exact="hepatitis" post="C.207 Dasabuvir is a non-nucleoside inhibitor that binds to"/>
  <result pre="induces conformational change that makes RdRp incapable of elongating the" exact="viral" post="RNA.208 Repurposing of this drug can be useful as"/>
  <result pre="Sagar209 in order to identify possible in-silico interactions with different" exact="viral" post="proteins. According to the parameters in the study, Dasabuvir"/>
  <result pre="(present in the ACE2), Ï€- Ï€ interactions with Phe170b (S" exact="Protein" post="residue) and hydrogen bonds to ACE2 residues Glu35a and"/>
  <result pre="ACE2 residues Glu35a and Asp38a and Gly176b and Ser174b (S" exact="Protein" post="residue). The authors highlight the importance of repurposing drugs"/>
  <result pre="not only for the new coronavirus but for the next" exact="viral" post="outbreaks. 5.5.2 Darunavir Darunavir (33) (Fig. 6) is a"/>
  <result pre="Darunavir establishes high affinity bonds to HIV-1 protease forming a" exact="stable" post="complex, thereby selectively inhibiting polyprotein gag-pol coded by the"/>
  <result pre="coded by the virus. This prevents the formation of mature" exact="viral" post="particles.210 A report by Chinese researchers on February 4th,"/>
  <result pre="MT-DTI to identify commercially available drugs to act on SARS-CoV-2" exact="viral" post="proteins. They evaluated the binding affinities of 3.410 FDA-approved"/>
  <result pre="in the assay, darunavir was a surprise because, despite inhibiting" exact="viral" post="proteinase, the study showed that it binds to the"/>
  <result pre="to SARS-CoV 3CLpro via 17 residues. This difference explains the" exact="lower" post="binding energy values between darunavir and SARS-CoV 3CLpro. It"/>
  <result pre="the authors reported that dasatinib may be valuable against coronaviruses" exact="infections" post="if a dosing regimen that minimizes immunotoxicity while still"/>
  <result pre="if a dosing regimen that minimizes immunotoxicity while still blocking" exact="viral" post="replication can be defined. Results indicated this drug as"/>
  <result pre="prominently the BCR-ABL fusion oncoprotein (whose overactivation can lead to" exact="chronic" post="myeloid leukaemia, CML), c-kit (involved in gastrointestinal stromal tumours"/>
  <result pre="to chronic myeloid leukaemia, CML), c-kit (involved in gastrointestinal stromal" exact="tumours" post="development), platelet-derived growth factor receptor (PDGFR), and the native"/>
  <result pre="also shown in-vitro antiviral properties against several virus, such as" exact="infectious" post="bronchitis virus (a viral model for studying the role"/>
  <result pre="shown in-vitro antiviral properties against several virus, such as infectious" exact="bronchitis" post="virus (a viral model for studying the role of"/>
  <result pre="properties against several virus, such as infectious bronchitis virus (a" exact="viral" post="model for studying the role of tyrosine kinase activity"/>
  <result pre="with virusâ€&quot;cell fusion,218 and other RNA viruses including coxsackie virus,219" exact="hepatitis C" post="virus,220 Ebola,221 among others, mainly by blocking viral entry"/>
  <result pre="virus,219 hepatitis C virus,220 Ebola,221 among others, mainly by blocking" exact="viral" post="entry or egress from the host cell. Besides, this"/>
  <result pre="the endosome and subsequent release into the cytoplasm, thus preventing" exact="viral" post="entry and viral replication via ABL-mediated cytoskeletal rearrangement. In"/>
  <result pre="subsequent release into the cytoplasm, thus preventing viral entry and" exact="viral" post="replication via ABL-mediated cytoskeletal rearrangement. In a later phase"/>
  <result pre="that ABL2 is a new host cell protein required for" exact="viral" post="growth.222 Furthermore, evidences suggest that imatinib can modulate the"/>
  <result pre="broad spectrum antiviral with good results against parainfluenza, coronavirus, rotavirus," exact="hepatitis" post="and other respiratory infections.235, 236, 237, 238 Following oral"/>
  <result pre="with good results against parainfluenza, coronavirus, rotavirus, hepatitis and other" exact="respiratory" post="infections.235, 236, 237, 238 Following oral administration, NTZ is"/>
  <result pre="relation to antiviral activity, NTZ blocks the maturation of the" exact="viral" post="hemagglutinin at the post-translation stage in treatments against influenza."/>
  <result pre="NTZ. The antiviral effect of NTZ was verified for mouse" exact="astrocytoma" post="(DBT) and fibroblasts (17Cl-1).240 The DBT cells infected with"/>
  <result pre="treated with NTZ at 5â€¯ÂµM for 12â€¯h, after which the" exact="viral" post="titer (TCID50) was determined and viral N protein was"/>
  <result pre="12â€¯h, after which the viral titer (TCID50) was determined and" exact="viral" post="N protein was subjected to Western blot. Results show"/>
  <result pre="Results show the strong inhibitory effect of NTZ on the" exact="viral" post="titer.240In-vitro studies on NTZ or its metabolite tizoxanide were"/>
  <result pre="IC50 of 1â€¯Âµg/mL. On the other hand, NTZ inhibited the" exact="viral" post="N protein in bovine coronavirus L9 (Î²CoV-L9) and human"/>
  <result pre="as TNF-Î±, IL-2, IL-4, I-5, IL-6, IL-8 and IL-10 in" exact="peripheral" post="blood mononuclear cells (PBMCs). Suppressing the overproduction of cytokines"/>
  <result pre="aminoquinoline subclass. Both are quick-absorption synthetic drugs approved to treat" exact="malaria" post="(Plasmodium falciparum) by several regulating agencies in the world."/>
  <result pre="presence of hydroxyl group. They are currently used to treat" exact="autoimmune diseases" post="such as lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis as"/>
  <result pre="They are currently used to treat autoimmune diseases such as" exact="lupus erythematosus," post="antiphospholipid syndrome, rheumatoid arthritis as they have immunomodulatory and"/>
  <result pre="currently used to treat autoimmune diseases such as lupus erythematosus," exact="antiphospholipid syndrome," post="rheumatoid arthritis as they have immunomodulatory and antithrombosis properties.242,"/>
  <result pre="to treat autoimmune diseases such as lupus erythematosus, antiphospholipid syndrome," exact="rheumatoid arthritis" post="as they have immunomodulatory and antithrombosis properties.242, 243, 244"/>
  <result pre="treat autoimmune diseases such as lupus erythematosus, antiphospholipid syndrome, rheumatoid" exact="arthritis" post="as they have immunomodulatory and antithrombosis properties.242, 243, 244"/>
  <result pre="due to the elevated levels of cytokine caused by CoV" exact="infections" post="in humans.245 Fig. 7 Chemical structures of quinolines, macrolides"/>
  <result pre="report antiviral activity of CQ and HCQ as they impair" exact="viral" post="entry and release in different in-vitro and in-vivo models.243,"/>
  <result pre="defended by Patil, Singhal &amp;amp; Masand.242 A factor that facilitates" exact="viral" post="replication is the acidic pH of endosomes, lysosomes and"/>
  <result pre="during SARS-CoV-2 infection, which is a similar mechanism to other" exact="viral" post="infections in humans.249, 250, 251 The little difference between"/>
  <result pre="SARS-CoV-2 infection, which is a similar mechanism to other viral" exact="infections" post="in humans.249, 250, 251 The little difference between the"/>
  <result pre="of CQ is also known, and poisoning is related to" exact="cardiovascular" post="complications that can be fatal. Using either CQ or"/>
  <result pre="of antiviral activity of CQ as well as reports of" exact="viral" post="inhibition for both CQ and HCQ, including SARS virus.248,"/>
  <result pre="focused on the indication of CQ and HCQ against SARS-CoV-2" exact="infections" post="given the lack of necessary information on their mechanisms"/>
  <result pre="their mechanisms of action.248 The potential use of CQ against" exact="viral" post="infections, specially SARS-CoV-2, relies on non-clinical evidences, as argued"/>
  <result pre="authors defend the in-vitro efficacy of CQ as it reduces" exact="viral" post="replication of SARS-CoV-2 and CQ is already known for"/>
  <result pre="replication of SARS-CoV-2 and CQ is already known for blocking" exact="viral" post="infections by increasing endosome pH and for interfering with"/>
  <result pre="of SARS-CoV-2 and CQ is already known for blocking viral" exact="infections" post="by increasing endosome pH and for interfering with glycosylation"/>
  <result pre="by increasing endosome pH and for interfering with glycosylation of" exact="viral" post="cell receptors. They also claim that the immunomodulatory potential"/>
  <result pre="assistance. Singh et al.258 defend that, in spite of the" exact="limited" post="evidences of CQ and HCQ against the new coronavirus,"/>
  <result pre="coronavirus, and considering its potentially favourable risk-benefit relation in the" exact="absence of" post="a valid treatment, both are useful in the present"/>
  <result pre="HCQ (six of which also received azithromycin) and to the" exact="short" post="observation time (6â€¯days) for all 16 control patients included"/>
  <result pre="control patients included in the final analysis. In addition, the" exact="absence of" post="a randomized investigation and no report on adverse effects"/>
  <result pre="Azithromycin exclusively, or both drugs had greater chances of developing" exact="diabetes" post="than control group. Mortality rate did not show significant"/>
  <result pre="used in the treatment of tropical diseases, such as onchocerciasis," exact="lymphatic filariasis," post="strongyloidiasis and lice. There is also evidence of its"/>
  <result pre="the treatment of tropical diseases, such as onchocerciasis, lymphatic filariasis," exact="strongyloidiasis" post="and lice. There is also evidence of its effectiveness"/>
  <result pre="effectiveness in the management of myiasis, trichinosis, malaria, leishmaniasis, trypanosomiasis," exact="Chagas disease" post="and schistosomiasis as well as bed bugs, inflammatory skin"/>
  <result pre="in the management of myiasis, trichinosis, malaria, leishmaniasis, trypanosomiasis, Chagas" exact="disease" post="and schistosomiasis as well as bed bugs, inflammatory skin"/>
  <result pre="management of myiasis, trichinosis, malaria, leishmaniasis, trypanosomiasis, Chagas disease and" exact="schistosomiasis" post="as well as bed bugs, inflammatory skin lesions, epilepsy,"/>
  <result pre="well as bed bugs, inflammatory skin lesions, epilepsy, neurological diseases," exact="tuberculosis" post="and some cancers.265 It is known that ivermectin is"/>
  <result pre="of importin proteins (IMP Î±/Î²1)266 or even by targeting the" exact="viral" post="helicase,267, 268 which inhibits viral RNA replication. There are"/>
  <result pre="or even by targeting the viral helicase,267, 268 which inhibits" exact="viral" post="RNA replication. There are several studies showing the antiviral"/>
  <result pre="of ivermectin against HIV-1 and dengue virus,266 influenza,269 DENV 1â€&quot;4,270" exact="yellow fever" post="virus268 and west Nile virus.271 Based on the fact"/>
  <result pre="proteins have revealed a potential role for IMP Î±/Î²1 during" exact="infection" post="in signal-dependent nucleocytoplasmic shutting of the SARS-CoV nucleocapsid protein.272"/>
  <result pre="occurs in the nucleus of the host cell and the" exact="viral" post="DNA unites with the human DNA, undergoing successive mitoses,"/>
  <result pre="DNA unites with the human DNA, undergoing successive mitoses, releasing" exact="viral" post="proteins and infecting other healthy cells. At this point,"/>
  <result pre="point, ivermectin bonds to and destabilizes IMP Î±/Î²1, impeding the" exact="viral" post="protein of the CoV from bonding to importins and"/>
  <result pre="NPC to the nucleus of the host cell, thereby inhibiting" exact="viral" post="replication. In order to provide further scientific support to"/>
  <result pre="al.274 conducted in-vitro experiments on Vero-hSLAM cells. Two hours after" exact="infection" post="with SARS-CoV-2, a single 5â€¯Î¼M dose of ivermectin was"/>
  <result pre="of ivermectin was administered, which reduced in 5,000 times the" exact="viral" post="RNA in the samples for the first 48â€¯h. Data"/>
  <result pre="between HIF-1 and nuclear localization signals were affected by the" exact="hypoxia" post="mechanism on the cellular level. The authors concluded that"/>
  <result pre="drugs work in synergy: the HCQ would act as a" exact="primary" post="shield against the viral penetration through cellular membrane while"/>
  <result pre="the HCQ would act as a primary shield against the" exact="viral" post="penetration through cellular membrane while ivermectin reduced viral replication."/>
  <result pre="against the viral penetration through cellular membrane while ivermectin reduced" exact="viral" post="replication. However, there are no randomized clinical trials described"/>
  <result pre="anti-SARS-CoV-2 activity. Data also show that Arbidol not only mitigates" exact="viral infection" post="but also interferes with the release of intracellular vesicles"/>
  <result pre="activity. Data also show that Arbidol not only mitigates viral" exact="infection" post="but also interferes with the release of intracellular vesicles"/>
  <result pre="trials concluded that Arbidol plus LPV/RTV delayed the progression of" exact="pulmonary" post="injuries, compared to LPV/RTV in isolation; decreased the possibility"/>
  <result pre="injuries, compared to LPV/RTV in isolation; decreased the possibility of" exact="respiratory" post="and faecal transmission by reaching elevated faecal concentrations that"/>
  <result pre="and faecal transmission by reaching elevated faecal concentrations that interrupts" exact="viral" post="replication in the gastrointestinal system â€&quot; where there is"/>
  <result pre="(RZT) Rizatriptan (RZT) (41) (Fig. 7) is used to treat" exact="migraine" post="and is a selective receptor of serotonin (5-HT) type"/>
  <result pre="neuro-hormone can mitigate the extreme form of the disease, the" exact="acute" post="respiratory syndrome that has caused most deaths by SARS-CoV-2"/>
  <result pre="can mitigate the extreme form of the disease, the acute" exact="respiratory" post="syndrome that has caused most deaths by SARS-CoV-2 cases."/>
  <result pre="mitigate the extreme form of the disease, the acute respiratory" exact="syndrome" post="that has caused most deaths by SARS-CoV-2 cases. Despite"/>
  <result pre="Zika virus and Ebola by interfering with the process of" exact="viral" post="replication and entry in host cells.301 Emetine is an"/>
  <result pre="MERS-CoV.98, 302 Regarding SARS-CoV-2, in-vitro assays with emetine showed effective" exact="viral" post="inhibition at concentrations of 0.5â€¯ÂµM,109 which is much superior"/>
  <result pre="This drug displays antitumoral activity in the treatment of myeloid" exact="chronic" post="leukaemia. The mechanism of action implicates the ribosomal bond"/>
  <result pre="treatment of alcohol dependence.308, 309 DSF is used to treat" exact="alcohol dependence" post="because it irreversibly inhibits the acetaldehyde dehydrogenase enzyme and"/>
  <result pre="of the enzymes, suggesting broad-spectrum characteristics.311, 313 CoVs have two" exact="viral" post="enzymes, Mpro and PLpro, that are cysteine protease involved"/>
  <result pre="DSF, as mentioned, can covalently modify cysteine residues interfering with" exact="viral" post="replication313, 315 investigated whether DSF can inhibit MERS-CoV and"/>
  <result pre="vasodilation, reducing leukocyte migration to the inflammation site and increasing" exact="vascular" post="permeability.317 The promising results showed reduction in mortality for"/>
  <result pre="promising results showed reduction in mortality for cases with severe" exact="respiratory" post="complications and no significant results for cases that dispensed"/>
  <result pre="drug repurposing: Immunotherapeutic approaches Immunotherapy is an effective intervention in" exact="viral" post="infections. Most attempts at immunotherapy were successful in fighting"/>
  <result pre="155, 318, 319 In addition, according to the evidences from" exact="viral" post="infections (Ebola, Influenza, SARS and MERS), immunotherapeutic interventions can"/>
  <result pre="318, 319 In addition, according to the evidences from viral" exact="infections" post="(Ebola, Influenza, SARS and MERS), immunotherapeutic interventions can reduce"/>
  <result pre="infections (Ebola, Influenza, SARS and MERS), immunotherapeutic interventions can reduce" exact="viral" post="load and mortality rate of patients.320, 321 Development of"/>
  <result pre="resource to improve the survival rate of patients with several" exact="viral" post="infections such as H5N1 avian influenza,329 pandemic 2009 influenza"/>
  <result pre="to improve the survival rate of patients with several viral" exact="infections" post="such as H5N1 avian influenza,329 pandemic 2009 influenza A"/>
  <result pre="transfusions, the improvement in clinical status of patients was observed." exact="Viral" post="loads also decreased and became negative within 12â€¯days after"/>
  <result pre="nAbs titers increased following the transfusion. In spite of the" exact="limited" post="sample, the authors concluded that convalescent plasma transfusion benefited"/>
  <result pre="will be essential to reduce the severity of the disease," exact="viral" post="shedding and transmission to control future outbreaks. Prior to"/>
  <result pre="vaccines employed live-attenuated virus vaccines, killed virus, DNA vaccines and" exact="viral" post="vector vaccines. Theoretically, these techniques could be applied to"/>
  <result pre="genomic perspective and the mechanisms employed in the invasion and" exact="infection" post="of host cells.325 Gao et al.341 promoted the pilot-scale"/>
  <result pre="different doses (3â€¯Î¼g or 6â€¯Î¼g per dose) in macaques provided" exact="partial" post="or complete protection against the SARS-CoV-2 challenge, respectively, without"/>
  <result pre="(3â€¯Î¼g or 6â€¯Î¼g per dose) in macaques provided partial or" exact="complete" post="protection against the SARS-CoV-2 challenge, respectively, without observable antibody-dependent"/>
  <result pre="They also must demand preclinical evidences that experimental vaccines prevent" exact="infection" post="â€&quot; even if it means waiting weeks or months"/>
  <result pre="potential relies on the mechanism for other viruses, such as" exact="Hepatitis" post="C, by inducing conformational changes that compromise RdRp activity."/>
  <result pre="was also possible to identify benzene derivatives used to treat" exact="cancer" post="(Dasatinib and Imatinib) and one antiviral (Darunavir), but predominant"/>
  <result pre="indole derivatives, Arbidol was pointed out as useful for reducing" exact="viral" post="binding and releasing of intracellular vacuoles that contain the"/>
  <result pre="calm and openness to question and refute hypotheses, in the" exact="absence of" post="scientific evidence to support their use to treat COVID-19."/>
  <result pre="of practices involving patients with the extreme form of the" exact="disease" post="is also important to identify new alternatives, such as"/>
  <result pre="dÃ©jÃ vu, due to the lack of antivirals to treat" exact="disease" post="as previous and the current pandemic,186 will be repeated"/>
  <result pre="current pandemic,186 will be repeated several times in future new" exact="viral" post="outbreaks. In relation to immunotherapy development, several technological platforms"/>
  <result pre="drugs by computational methodsActa Pharm Sin B10202076678810.1016/j.apsb.2020.02.00832292689 6MercorelliB.PalÃ¹G.LoregianA.Drug repurposing for" exact="viral" post="infectious diseases: how far are we?Trends Microbiol26201886587610.1016/j.tim.2018.04.00429759926 7ElfikyA.A.Ribavirin, Remdesivir,"/>
  <result pre="by computational methodsActa Pharm Sin B10202076678810.1016/j.apsb.2020.02.00832292689 6MercorelliB.PalÃ¹G.LoregianA.Drug repurposing for viral" exact="infectious" post="diseases: how far are we?Trends Microbiol26201886587610.1016/j.tim.2018.04.00429759926 7ElfikyA.A.Ribavirin, Remdesivir, Sofosbuvir,"/>
  <result pre="COVID-19 main proteaseLife Sci251202011762710.1016/j.lfs.2020.117627 9RichardsonP.GriffinI.TuckerC.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet3952020e30e3110.1016/S0140-6736(20)30304-432032529 10ShannonA.LeN.T.T.SeliskoB.Remdesivir and SARS-CoV-2: Structural requirements at both"/>
  <result pre="main proteaseLife Sci251202011762710.1016/j.lfs.2020.117627 9RichardsonP.GriffinI.TuckerC.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet3952020e30e3110.1016/S0140-6736(20)30304-432032529 10ShannonA.LeN.T.T.SeliskoB.Remdesivir and SARS-CoV-2: Structural requirements at both nsp12"/>
  <result pre="potential treatment for 2019-nCoV acute respiratory diseaseLancet3952020e30e3110.1016/S0140-6736(20)30304-432032529 10ShannonA.LeN.T.T.SeliskoB.Remdesivir and SARS-CoV-2:" exact="Structural" post="requirements at both nsp12 RdRp and nsp14 Exonuclease active-sitesAntiviral"/>
  <result pre="229EJ Clin Microbiol4320055452545610.1128/JCM.43.11.5452-5456.200516272469 13PeirisJ.LaiS.PoonL.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndromeLancet36120031319132510.1016/S0140-6736(03)13077-212711465 14ZakiA.M.van BoheemenS.BestebroerT.M.OsterhausA.D.M.E.FouchierR.A.M.Isolation of a novel coronavirus from"/>
  <result pre="Clin Microbiol4320055452545610.1128/JCM.43.11.5452-5456.200516272469 13PeirisJ.LaiS.PoonL.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndromeLancet36120031319132510.1016/S0140-6736(03)13077-212711465 14ZakiA.M.van BoheemenS.BestebroerT.M.OsterhausA.D.M.E.FouchierR.A.M.Isolation of a novel coronavirus from a"/>
  <result pre="14ZakiA.M.van BoheemenS.BestebroerT.M.OsterhausA.D.M.E.FouchierR.A.M.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med36720121814182010.1056/NEJMoa121172123075143 15SinghalT.A review of"/>
  <result pre="coronavirus 2019-nCoV: need for rapid vaccine and biologics developmentPathogens9202014810.3390/pathogens9020148 17ZhouP.YangX.-L.WangX.-G.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="new coronavirus of probable bat originNature579202027027310.1038/s41586-020-2012-732015507 18World Health Organization. Coronavirus" exact="disease" post="(COVID-19) pandemic. Updated May 26, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Accessed Jun"/>
  <result pre="Virus Res20118516410.1016/B978-0-12-385885-6.00009-222094080 20VellingiriB.JayaramayyaK.IyerM.COVID-19: A promising cure for the global panicSci" exact="Total" post="Environ202010.1016/j.scitotenv.2020.138277 21MousavizadehL.GhasemiS.Genotype and phenotype of COVID-19: Their roles in"/>
  <result pre="29RedelmeierD.A.ShafirE.Pitfalls of judgment during the COVID-19 pandemicLancet Public Heal52020e306e30810.1016/S2468-2667(20)30096-7 30ChanJ.F.-W.YuanS.KokK.-H.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="during the COVID-19 pandemicLancet Public Heal52020e306e30810.1016/S2468-2667(20)30096-7 30ChanJ.F.-W.YuanS.KokK.-H.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="family clusterLancet395202051452310.1016/S0140-6736(20)30154-931986261 31SethuramanN.JeremiahS.S.RyoA.Interpreting diagnostic tests for SARS-CoV-2JAMA3232020224910.1001/jama.2020.825932374370 32ToK.K.-W.TsangO.T.-Y.LeungW.-S.Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
  <result pre="diagnostic tests for SARS-CoV-2JAMA3232020224910.1001/jama.2020.825932374370 32ToK.K.-W.TsangO.T.-Y.LeungW.-S.Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
  <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort studyLancet Infect Dis20202056557410.1016/S1473-3099(20)30196-132213337 33KrupovicM.DoljaV.V.KooninE.V.Origin"/>
  <result pre="York; 2015. https://doi.org/10.1007/978-1-4939-2438-7. 40JiangF.DengL.ZhangL.CaiY.CheungC.W.XiaZ.Review of the clinical characteristics of coronavirus" exact="disease" post="2019 (COVID-19)J Gen Intern Med3520201545154910.1007/s11606-020-05762-w32133578 41GandhiR.T.LynchJ.B.del RioC.Mild or moderate"/>
  <result pre="41GandhiR.T.LynchJ.B.del RioC.Mild or moderate Covid-19NEJMcp2009249N Engl J Med202010.1056/NEJMcp2009249 42AronsM.M.HatfieldK.M.ReddyS.C.Presymptomatic SARS-CoV-2" exact="infections" post="and transmission in a skilled nursing facilityN Engl J"/>
  <result pre="J Med38220202081209010.1056/NEJMoa200845732329971 43GuoY.-R.CaoQ.-D.HongZ.-S.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak â€&quot; an update on the statusMil"/>
  <result pre="Wuhan, ChinaLancet395202049750610.1016/S0140-6736(20)30183-531986264 45ZhouF.YuT.DuR.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="Wuhan, China: a retrospective cohort studyLancet39520201054106210.1016/S0140-6736(20)30566-332171076 46GuanW.NiZ.HuY.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med38220201708172010.1056/NEJMoa200203232109013 47YangX.YuY.XuJ.Clinical course and"/>
  <result pre="47YangX.YuY.XuJ.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir"/>
  <result pre="a single-centered, retrospective, observational studyLancet Respir Med8202047548110.1016/S2213-2600(20)30079-532105632 48FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
  <result pre="retrospective, observational studyLancet Respir Med8202047548110.1016/S2213-2600(20)30079-532105632 48FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir Med82020e2110.1016/S2213-2600(20)30116-8 49WangT.DuZ.ZhuF.Comorbidities"/>
  <result pre="implications in cardiovascular, hypertensive and kidney diseasesPharmacol Res2017125211253810.1016/j.phrs.2017.06.005 51LiH.LiuL.ZhangD.SARS-CoV-2 and" exact="viral" post="sepsis: observations and hypothesesLancet39520201517152010.1016/S0140-6736(20)30920-X32311318 52MoP.XingY.XiaoY.Clinical characteristics of refractory COVID-19"/>
  <result pre="viral sepsis: observations and hypothesesLancet39520201517152010.1016/S0140-6736(20)30920-X32311318 52MoP.XingY.XiaoY.Clinical characteristics of refractory COVID-19" exact="pneumonia" post="in Wuhan, ChinaClin Infect Dis202010.1093/cid/ciaa270[Epub ahead of print] 53Borges"/>
  <result pre="ChinaClin Infect Dis202010.1093/cid/ciaa270[Epub ahead of print] 53Borges do NascimentoI.J.CacicN.AbdulazeemH.M.Novel coronavirus" exact="infection" post="(COVID-19) in humans: a scoping review and meta-analysisJ Clin"/>
  <result pre="54La VigneraS.CannarellaR.CondorelliR.A.TorreF.AversaA.CalogeroA.E.Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of" exact="venous thromboembolism" post="and hypovitaminosis DInt J Mol Sci212020294810.3390/ijms21082948 55MakJ.W.Y.ChanF.K.L.NgS.C.Probiotics and COVID-19:"/>
  <result pre="Gastroenterol Hepatol5202064464510.1016/S2468-1253(20)30122-932339473 56ChenT.WuD.ChenH.retrospective studyBMJ20202019m109110.1136/bmj.m1091 57XuZ.ShiL.WangY.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med8202042042210.1016/S2213-2600(20)30076-X32085846 58ZhangC.ShiL.WangF.-S.Liver injury in COVID-19:"/>
  <result pre="Hepatol5202064464510.1016/S2468-1253(20)30122-932339473 56ChenT.WuD.ChenH.retrospective studyBMJ20202019m109110.1136/bmj.m1091 57XuZ.ShiL.WangY.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med8202042042210.1016/S2213-2600(20)30076-X32085846 58ZhangC.ShiL.WangF.-S.Liver injury in COVID-19: management"/>
  <result pre="injury in COVID-19: management and challengesLancet Gastroenterol Hepatol5202042843010.1016/S2468-1253(20)30057-132145190 59VargaZ.FlammerA.J.SteigerP.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet39520201417141810.1016/S0140-6736(20)30937-532325026 60LiG.FanY.LaiY.Coronavirus infections and immune responsesJ"/>
  <result pre="Gastroenterol Hepatol5202042843010.1016/S2468-1253(20)30057-132145190 59VargaZ.FlammerA.J.SteigerP.Endothelial cell infection and endotheliitis in COVID-19Lancet39520201417141810.1016/S0140-6736(20)30937-532325026 60LiG.FanY.LaiY.Coronavirus" exact="infections" post="and immune responsesJ Med Virol92202042443210.1002/jmv.2568531981224 61LiuJ.LiS.LiuJ.Longitudinal characteristics of lymphocyte"/>
  <result pre="61LiuJ.LiS.LiuJ.Longitudinal characteristics of lymphocyte responses and cytokine profiles in the" exact="peripheral" post="blood of SARS-CoV-2 infected patients55102763EBioMedicine202010.1016/j.ebiom.2020.102763 62ZumlaA.HuiD.S.AzharE.I.MemishZ.A.MaeurerM.Reducing mortality from 2019-nCoV:"/>
  <result pre="an optionLancet3952020e35e3610.1016/S0140-6736(20)30305-632035018 63OmraniA.S.SaadM.M.BaigK.Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: a retrospective cohort studyLancet Infect Dis1420141090109510.1016/S1473-3099(14)70920-X25278221"/>
  <result pre="optionLancet3952020e35e3610.1016/S0140-6736(20)30305-632035018 63OmraniA.S.SaadM.M.BaigK.Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: a retrospective cohort studyLancet Infect Dis1420141090109510.1016/S1473-3099(14)70920-X25278221 64TangT.BidonM.JaimesJ.A.WhittakerG.R.DanielS.Coronavirus"/>
  <result pre="by neutralizing antibodiesJ Virol8720135502551110.1128/JVI.00128-1323468491 70GlowackaI.BertramS.MullerM.A.Evidence that TMPRSS2 activates the severe" exact="acute" post="respiratory syndrome coronavirus spike protein for membrane fusion and"/>
  <result pre="neutralizing antibodiesJ Virol8720135502551110.1128/JVI.00128-1323468491 70GlowackaI.BertramS.MullerM.A.Evidence that TMPRSS2 activates the severe acute" exact="respiratory" post="syndrome coronavirus spike protein for membrane fusion and reduces"/>
  <result pre="antibodiesJ Virol8720135502551110.1128/JVI.00128-1323468491 70GlowackaI.BertramS.MullerM.A.Evidence that TMPRSS2 activates the severe acute respiratory" exact="syndrome" post="coronavirus spike protein for membrane fusion and reduces viral"/>
  <result pre="respiratory syndrome coronavirus spike protein for membrane fusion and reduces" exact="viral" post="control by the humoral immune responseJ Virol8520114122413410.1128/JVI.02232-1021325420 71Iwata-YoshikawaN.OkamuraT.ShimizuY.HasegawaH.TakedaM.NagataN.TMPRSS2 contributes"/>
  <result pre="coronavirus infectionJ Virol93201910.1128/JVI.01815-18 72KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
  <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entryJ Virol8620126537654510.1128/JVI.00094-1222496216 73MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the"/>
  <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entryJ Virol8620126537654510.1128/JVI.00094-1222496216 73MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe"/>
  <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entryJ Virol8620126537654510.1128/JVI.00094-1222496216 73MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe acute"/>
  <result pre="respiratory syndrome coronavirus entryJ Virol8620126537654510.1128/JVI.00094-1222496216 73MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe" exact="acute" post="respiratory syndrome coronavirus spike protein by the transmembrane protease"/>
  <result pre="syndrome coronavirus entryJ Virol8620126537654510.1128/JVI.00094-1222496216 73MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe acute" exact="respiratory" post="syndrome coronavirus spike protein by the transmembrane protease TMPRSS2J"/>
  <result pre="coronavirus entryJ Virol8620126537654510.1128/JVI.00094-1222496216 73MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe acute respiratory" exact="syndrome" post="coronavirus spike protein by the transmembrane protease TMPRSS2J Virol842010126581266410.1128/JVI.01542-1020926566"/>
  <result pre="Virol842010126581266410.1128/JVI.01542-1020926566 74ShullaA.Heald-SargentT.SubramanyaG.ZhaoJ.PerlmanS.GallagherT.A transmembrane serine protease is linked to the severe" exact="acute" post="respiratory syndrome coronavirus receptor and activates virus entryJ Virol85201187388210.1128/jvi.02062-1021068237"/>
  <result pre="74ShullaA.Heald-SargentT.SubramanyaG.ZhaoJ.PerlmanS.GallagherT.A transmembrane serine protease is linked to the severe acute" exact="respiratory" post="syndrome coronavirus receptor and activates virus entryJ Virol85201187388210.1128/jvi.02062-1021068237 75ZhouY.VedanthamP.LuK.Protease"/>
  <result pre="transmembrane serine protease is linked to the severe acute respiratory" exact="syndrome" post="coronavirus receptor and activates virus entryJ Virol85201187388210.1128/jvi.02062-1021068237 75ZhouY.VedanthamP.LuK.Protease inhibitors"/>
  <result pre="termination determines the inhibition potency of 2â€²-modified nucleotide analogs against" exact="hepatitis C" post="virus polymeraseAntimicrob Agents Chemother5820143636364510.1128/AAC.02666-1424733478 82ChenY.ZhengH.ZhangJ.WangL.JinZ.GaoW.Protective effect and potential mechanisms"/>
  <result pre="and potential mechanisms of Wei-Chang-An pill on high-dose 5-fluorouracil-induced intestinal" exact="mucositis" post="in miceJ Ethnopharmacol201619020019021110.1016/j.jep.2016.05.057 83ChitrakarI.Kim-HolzapfelD.M.ZhouW.FrenchJ.B.Higher order structures in purine and"/>
  <result pre="and evaluation of anti-tumor activity of novel triazolo[1,5-a] pyrimidine on" exact="cancer" post="cells by induction of cellular apoptosis and inhibition of"/>
  <result pre="gastrointestinal cancersJ Immunother Cancer420166510.1186/s40425-016-0163-827777774 92PereiraV.B.M.MeloA.T.Assis-JÃºniorE.M.A new animal model of intestinal" exact="mucositis" post="induced by the combination of irinotecan and 5-fluorouracil in"/>
  <result pre="Rev Anticancer Ther16201625527110.1586/14737140.2016.114377726781169 96JiangY.HanZ.WangY.HaoW.Depletion of SIRT7 sensitizes human non-small cell" exact="lung cancer" post="cells to gemcitabine therapy by inhibiting autophagyBiochem Biophys Res"/>
  <result pre="Anticancer Ther16201625527110.1586/14737140.2016.114377726781169 96JiangY.HanZ.WangY.HaoW.Depletion of SIRT7 sensitizes human non-small cell lung" exact="cancer" post="cells to gemcitabine therapy by inhibiting autophagyBiochem Biophys Res"/>
  <result pre="gemcitabine therapy by inhibiting autophagyBiochem Biophys Res Commun506201826627110.1016/j.bbrc.2018.10.08930348528 97BergT.NÃ¸ttrupT.J.RoedH.Gemcitabine for" exact="recurrent" post="ovarian cancer - a systematic review and meta-analysisGynecol Oncol155201953053710.1016/j.ygyno.2019.09.02631604664"/>
  <result pre="therapy by inhibiting autophagyBiochem Biophys Res Commun506201826627110.1016/j.bbrc.2018.10.08930348528 97BergT.NÃ¸ttrupT.J.RoedH.Gemcitabine for recurrent" exact="ovarian cancer" post="- a systematic review and meta-analysisGynecol Oncol155201953053710.1016/j.ygyno.2019.09.02631604664 98DyallJ.ColemanC.M.HartB.J.Repurposing of"/>
  <result pre="by inhibiting autophagyBiochem Biophys Res Commun506201826627110.1016/j.bbrc.2018.10.08930348528 97BergT.NÃ¸ttrupT.J.RoedH.Gemcitabine for recurrent ovarian" exact="cancer" post="- a systematic review and meta-analysisGynecol Oncol155201953053710.1016/j.ygyno.2019.09.02631604664 98DyallJ.ColemanC.M.HartB.J.Repurposing of"/>
  <result pre="98DyallJ.ColemanC.M.HartB.J.Repurposing of clinically developed drugs for treatment of middle east" exact="respiratory" post="syndrome coronavirus infectionAntimicrob Agents Chemother5820144885489310.1128/AAC.03036-1424841273 99SerafinM.B.BottegaA.FolettoV.S.da RosaT.F.HÃ¶rnerA.HÃ¶rnerR.Drug repositioning is"/>
  <result pre="of clinically developed drugs for treatment of middle east respiratory" exact="syndrome" post="coronavirus infectionAntimicrob Agents Chemother5820144885489310.1128/AAC.03036-1424841273 99SerafinM.B.BottegaA.FolettoV.S.da RosaT.F.HÃ¶rnerA.HÃ¶rnerR.Drug repositioning is an"/>
  <result pre="antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting" exact="vascular" post="endothelial growth factor and platelet-derived growth factor receptors: determination"/>
  <result pre="and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin" exact="Cancer" post="Res9200332733712538485 103MendelsohnJ.BaselgaJ.The EGF receptor family as targets for cancer"/>
  <result pre="relationshipClin Cancer Res9200332733712538485 103MendelsohnJ.BaselgaJ.The EGF receptor family as targets for" exact="cancer" post="therapyOncogene1920006550656511426640 104Praveen D, Puvvada RC, M VA. Janus kinase"/>
  <result pre="diseases by a novel broad-spectrum nucleoside analogue BCX4430Nature508201440240510.1038/nature1302724590073 106WestoverJ.B.MathisA.TaylorR.Galidesivir limits" exact="Rift Valley fever" post="virus infection and disease in Syrian golden hamstersAntiviral Res2018156381564510.1016/j.antiviral.2018.05.013"/>
  <result pre="novel broad-spectrum nucleoside analogue BCX4430Nature508201440240510.1038/nature1302724590073 106WestoverJ.B.MathisA.TaylorR.Galidesivir limits Rift Valley fever" exact="virus infection" post="and disease in Syrian golden hamstersAntiviral Res2018156381564510.1016/j.antiviral.2018.05.013 107LiG.De ClercqE.Therapeutic"/>
  <result pre="broad-spectrum nucleoside analogue BCX4430Nature508201440240510.1038/nature1302724590073 106WestoverJ.B.MathisA.TaylorR.Galidesivir limits Rift Valley fever virus" exact="infection" post="and disease in Syrian golden hamstersAntiviral Res2018156381564510.1016/j.antiviral.2018.05.013 107LiG.De ClercqE.Therapeutic"/>
  <result pre="analogue BCX4430Nature508201440240510.1038/nature1302724590073 106WestoverJ.B.MathisA.TaylorR.Galidesivir limits Rift Valley fever virus infection and" exact="disease" post="in Syrian golden hamstersAntiviral Res2018156381564510.1016/j.antiviral.2018.05.013 107LiG.De ClercqE.Therapeutic options for"/>
  <result pre="and subtype profiling of PSI-7977 as a nucleotide inhibitor of" exact="hepatitis C" post="virusAntimicrob Agents Chemother5620123359336810.1128/AAC.00054-1222430955 111Pastuch-GawoÅ‚ekG.GillnerD.KrÃ³lE.WalczakK.WandzikI.Selected nucleos(t)ide-based prescribed drugs and their"/>
  <result pre="Biol Chem2852010343373434710.1074/jbc.M110.16180220801890 113XuH.-T.Colby-GerminarioS.P.HassounahS.A.Evaluation of Sofosbuvir (Î²-D-2â€²-deoxy-2â€²-Î±-fluoro-2â€²-Î²-C-methyluridine) as an inhibitor of" exact="Dengue" post="virus replicationSci Rep72017634510.1038/s41598-017-06612-228740124 114de Freitas CS, Higa LM, Sacramento"/>
  <result pre="Rep72017634510.1038/s41598-017-06612-228740124 114de Freitas CS, Higa LM, Sacramento CQ, et al." exact="Yellow fever" post="virus is susceptible to sofosbuvir both in vitro and"/>
  <result pre="al. Beyond members of the flaviviridae family, sofosbuvir also inhibits" exact="chikungunya" post="virus replication. Antimicrob Agents Chemother 2018;63:e01389-18. https://doi.org/10.1128/AAC.01389-18. 117Sayad B,"/>
  <result pre="Bridges EG, Placidi L, et al. Antiviral Î²-L-nucleosides specific for" exact="hepatitis" post="B virus infection. In: Frontiers in Viral Hepatitis. Elsevier;"/>
  <result pre="Placidi L, et al. Antiviral Î²-L-nucleosides specific for hepatitis B" exact="virus infection." post="In: Frontiers in Viral Hepatitis. Elsevier; 2003. p 245â€&quot;261."/>
  <result pre="Î²-L-nucleosides specific for hepatitis B virus infection. In: Frontiers in" exact="Viral" post="Hepatitis. Elsevier; 2003. p 245â€&quot;261. https://doi.org/10.1016/B978-044450986-4/50072-2. 120LuiY.Y.N.ChanH.L.Y.Treatment of chronic"/>
  <result pre="in Viral Hepatitis. Elsevier; 2003. p 245â€&quot;261. https://doi.org/10.1016/B978-044450986-4/50072-2. 120LuiY.Y.N.ChanH.L.Y.Treatment of" exact="chronic hepatitis" post="B: focus on telbivudineExpert Rev Anti Infect Ther7200925926810.1586/eri.09.619344240 121Whalen"/>
  <result pre="Viral Hepatitis. Elsevier; 2003. p 245â€&quot;261. https://doi.org/10.1016/B978-044450986-4/50072-2. 120LuiY.Y.N.ChanH.L.Y.Treatment of chronic" exact="hepatitis" post="B: focus on telbivudineExpert Rev Anti Infect Ther7200925926810.1586/eri.09.619344240 121Whalen"/>
  <result pre="2016. 122OsbornM.Safety and efficacy of telbivudine for the treatment of" exact="chronic hepatitis" post="BTher Clin Risk Manag200978910.2147/TCRM.S531819851526 123ZhaoT.-Q.ZhaoY.-D.LiuX.-Y.Novel 3-(2,6,9-trisubstituted-9H-purine)-8-chalcone derivatives as potent"/>
  <result pre="122OsbornM.Safety and efficacy of telbivudine for the treatment of chronic" exact="hepatitis" post="BTher Clin Risk Manag200978910.2147/TCRM.S531819851526 123ZhaoT.-Q.ZhaoY.-D.LiuX.-Y.Novel 3-(2,6,9-trisubstituted-9H-purine)-8-chalcone derivatives as potent"/>
  <result pre="BTher Clin Risk Manag200978910.2147/TCRM.S531819851526 123ZhaoT.-Q.ZhaoY.-D.LiuX.-Y.Novel 3-(2,6,9-trisubstituted-9H-purine)-8-chalcone derivatives as potent anti-gastric" exact="cancer" post="agents: design, synthesis and structural optimizationEur J Med Chem161201949350510.1016/j.ejmech.2018.10.05830388465"/>
  <result pre="group of purine-2,6-dione derivatives as potent modulators of airway smooth" exact="muscle" post="cell remodellingEur J Pharmacol865201917277910.1016/j.ejphar.2019.172779 125ChÅ‚oÅ&quot;-RzepaG.JankowskaA.ÅšlusarczykM.Novel butanehydrazide derivatives of purine-2,6-dione"/>
  <result pre="in rhesus monkeysNature531201638138510.1038/nature1718026934220 132MulanguS.DoddL.E.DaveyR.T.A randomized, controlled trial of ebola virus" exact="disease" post="therapeuticsN Engl J Med38120192293230310.1056/NEJMoa191099331774950 133SheahanT.P.SimsA.C.GrahamR.L.Broad-spectrum antiviral GS-5734 inhibits both"/>
  <result pre="with severe Covid-19N Engl J Med38220202327233610.1056/NEJMoa200701632275812 137SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic treatments for coronavirus" exact="disease" post="2019 (COVID-19)JAMA202010.1001/jama.2020.6019[Epub ahead of print] 138MartinD.F.KuppermannB.D.WolitzR.A.PalestineA.G.LiH.RobinsonC.A.Oral ganciclovir for patients"/>
  <result pre="(COVID-19)JAMA202010.1001/jama.2020.6019[Epub ahead of print] 138MartinD.F.KuppermannB.D.WolitzR.A.PalestineA.G.LiH.RobinsonC.A.Oral ganciclovir for patients with cytomegalovirus" exact="retinitis" post="treated with a ganciclovir implantN Engl J Med34019991063107010.1056/NEJM19990408340140210194235 139Wishart"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 141MontesinosP.SanzJ.CanteroS.Incidence, risk factors,"/>
  <result pre="China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 141MontesinosP.SanzJ.CanteroS.Incidence, risk factors, and outcome of" exact="cytomegalovirus infection" post="and disease in patients receiving prophylaxis with oral valganciclovir"/>
  <result pre="a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 141MontesinosP.SanzJ.CanteroS.Incidence, risk factors, and outcome of cytomegalovirus" exact="infection" post="and disease in patients receiving prophylaxis with oral valganciclovir"/>
  <result pre="studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 141MontesinosP.SanzJ.CanteroS.Incidence, risk factors, and outcome of cytomegalovirus infection and" exact="disease" post="in patients receiving prophylaxis with oral valganciclovir or intravenous"/>
  <result pre="oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantationBiol" exact="Blood" post="Marrow Transplant15200973074010.1016/j.bbmt.2009.03.00219450758 142WinstonD.J.BadenL.R.GabrielD.A.Pharmacokinetics of ganciclovir after oral valganciclovir versus"/>
  <result pre="intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host" exact="disease" post="of the gastrointestinal tractBiol Blood Marrow Transplant12200663564010.1016/j.bbmt.2005.12.03816737936 143MarkhamA.FauldsD.GanciclovirDrugs48199445548410.2165/00003495-199448030-000097527763 144YanY.ShinW.I.PangY.X.The"/>
  <result pre="cell transplant patients with graft-versus-host disease of the gastrointestinal tractBiol" exact="Blood" post="Marrow Transplant12200663564010.1016/j.bbmt.2005.12.03816737936 143MarkhamA.FauldsD.GanciclovirDrugs48199445548410.2165/00003495-199448030-000097527763 144YanY.ShinW.I.PangY.X.The first 75 days of novel"/>
  <result pre="challengesJ Microbiol Immunol Infect53202043644310.1016/j.jmii.2020.03.03432307245 156MartinezM.A.Compounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirusAntimicrob Agents Chemother202010.1128/AAC.00399-20 157KorenG.KingS.KnowlesS.PhillipsE.Ribavirin in the treatment of"/>
  <result pre="treated with favipiravirAntiviral Res2015123701237710.1016/j.antiviral.2015.08.015 162FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad-spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Japan Acad Ser B93201744946310.2183/pjab.93.02728769016 163Chen C, Huang"/>
  <result pre="â€&quot; the search for effective therapyN Engl J Med38220201851185210.1056/NEJMe200547732187463 168LiH.LiuS.-M.YuX.-H.TangS.-L.TangC.-K.Coronavirus" exact="disease" post="2019 (COVID-19): current status and future perspectivesInt J Antimicrob"/>
  <result pre="findingsThorax59200425225610.1136/thorax.2003.01265814985565 170ChanJ.F.-W.YaoY.YeungM.-L.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
  <result pre="171KimU.J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C.Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East" exact="respiratory" post="syndrome: a case reportAntivir Ther21201545545910.3851/IMP300226492219 172CaoB.WangY.WenD.A trial of lopinavir-ritonavir"/>
  <result pre="of the binding abilities of ritonavir and lopinavir to wuhan" exact="pneumonia" post="coronavirus proteasesBioRxiv202010.1101/2020.01.31.929695 175UyekiT.M.Oseltamivir treatment of influenza in childrenClin Infect"/>
  <result pre="binding free energy calculationBioRxiv202010.1101/2020.01.27.921627 182BustiA.J.HallR.G.MargolisD.M.Atazanavir for the treatment of human" exact="immunodeficiency" post="virus infectionPharmacotherapy12200417321747 183MastanS.K.KumarK.E.Influence of atazanavir on the pharmacodynamics and"/>
  <result pre="the pharmacodynamics and pharmacokinetics of gliclazide in animal modelsInt J" exact="Diabetes" post="Dev Ctries220105660 184HaasD.W.ZalacC.SchraderdS.Therapy with atazanavir plus saquinavir in patients"/>
  <result pre="that potentially bind into the SARS-CoV-2 main protease, essential for" exact="viral" post="replicationJ Biomol Struct Dyn202010.1080/07391102.2020.1764393 189BrogdenR.N.ToddP.A.SorkinE.M.CaptoprilDrugs3619885406003063499 190HausenloyD.Boston-GriffithsE.YellonD.Cyclosporin A and cardioprotection:"/>
  <result pre="193CourM.OvizeM.ArgaudL.Cyclosporine A: a valid candidate to treat COVID-19 patients with" exact="acute" post="respiratory failure?Crit Care24202027632487139 194PfefferleS.SchÃ¶pfJ.KÃ¶glM.The SARS-coronavirus-host interactome: identification of cyclophilins"/>
  <result pre="A: a valid candidate to treat COVID-19 patients with acute" exact="respiratory" post="failure?Crit Care24202027632487139 194PfefferleS.SchÃ¶pfJ.KÃ¶glM.The SARS-coronavirus-host interactome: identification of cyclophilins as"/>
  <result pre="https://doi.org/10.13140/RG.2.2.34276.94083. 200CureE.KucukA.Cumhur CureM.Cyclosporine therapy in cytokine storm due to coronavirus" exact="disease" post="2019 (COVID-19)Rheumatol Int4020201177117932415310 201CampanaC.RegazziM.B.BuggiaI.MolinaroM.Clinically significant drug interactions with cyclosporinClin"/>
  <result pre="endosome/lysosome and block the entry of Ebola Virus, Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus"/>
  <result pre="and block the entry of Ebola Virus, Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)J"/>
  <result pre="Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV)J Biol Chem29120169218923226953343 203AndersenP.I.IanevskiA.LysvandH.Discovery and development"/>
  <result pre="Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV)J Biol Chem29120169218923226953343 203AndersenP.I.IanevskiA.LysvandH.Discovery and development of"/>
  <result pre="Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV)J Biol Chem29120169218923226953343 203AndersenP.I.IanevskiA.LysvandH.Discovery and development of safe-in-man"/>
  <result pre="208GentileI.BuonomoA.R.BorgiaG.Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of" exact="hepatitis C" post="virus infectionRev Recent Clin Trials9201411512324882169 209ShahB.PalmiM.SnehaR.In silico studies on"/>
  <result pre="the management of HIV-1 infectionDrugs74201399125 212DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov Ther142020586032147628 213AfaghiS.TarkiF.E.RahimiF.S.Therapeutic options and critical care"/>
  <result pre="219CoyneC.B.BergelsonJ.M.Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through" exact="epithelial" post="tight junctionsCell124200611913116413486 220MinS.LimY.S.ShinD.Abl tyrosine kinase regulates hepatitis C virus"/>
  <result pre="coxsackievirus entry through epithelial tight junctionsCell124200611913116413486 220MinS.LimY.S.ShinD.Abl tyrosine kinase regulates" exact="hepatitis C" post="virus entryFront Microbiol82017112928674529 221GarciaM.CooperA.ShiW.Productive replication of ebola virus is"/>
  <result pre="Transl Med42012123ra24 222ColemanC.M.SiskJ.M.MingoR.M.Abelson kinase inhibitors are potent inhibitors of severe" exact="acute" post="respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus"/>
  <result pre="Med42012123ra24 222ColemanC.M.SiskJ.M.MingoR.M.Abelson kinase inhibitors are potent inhibitors of severe acute" exact="respiratory" post="syndrome coronavirus and middle east respiratory syndrome coronavirus fusionJ"/>
  <result pre="222ColemanC.M.SiskJ.M.MingoR.M.Abelson kinase inhibitors are potent inhibitors of severe acute respiratory" exact="syndrome" post="coronavirus and middle east respiratory syndrome coronavirus fusionJ Virol9020168924893327466418"/>
  <result pre="inhibitors of severe acute respiratory syndrome coronavirus and middle east" exact="respiratory" post="syndrome coronavirus fusionJ Virol9020168924893327466418 223DoschS.F.MahajanS.D.CollinsA.R.SARS coronavirus spike protein-induced innate"/>
  <result pre="of severe acute respiratory syndrome coronavirus and middle east respiratory" exact="syndrome" post="coronavirus fusionJ Virol9020168924893327466418 223DoschS.F.MahajanS.D.CollinsA.R.SARS coronavirus spike protein-induced innate immune"/>
  <result pre="response occurs via activation of the NF-ÎºB pathway in human" exact="monocyte" post="macrophages in vitroVirus Res1422009192719185596 224RizzoA.N.SammaniS.EsquincaA.E.Imatinib attenuates inflammation and vascular"/>
  <result pre="human monocyte macrophages in vitroVirus Res1422009192719185596 224RizzoA.N.SammaniS.EsquincaA.E.Imatinib attenuates inflammation and" exact="vascular" post="leak in a clinically relevant two-hit model of acute"/>
  <result pre="and vascular leak in a clinically relevant two-hit model of" exact="acute" post="lung injuryAm J Physiol Cell Mol Physiol3092015L1294L1304 225BÃ¤rnthalerT.Imatinib stimulates"/>
  <result pre="severe refractory asthmaN Engl J Med37620171911192028514613 228MagroF.CostaC.Long-standing remission of Crohnâ€™s" exact="disease" post="under imatinib therapy in a patient with Crohnâ€™s diseaseInflamm"/>
  <result pre="the management and avoidance of adverse events of treatment in" exact="chronic" post="myeloid leukaemiaLeukemia3020161648167127121688 231MughalT.Principal long-term adverse effects of imatinib in"/>
  <result pre="leukaemiaLeukemia3020161648167127121688 231MughalT.Principal long-term adverse effects of imatinib in patients with" exact="chronic" post="myeloid leukemia in chronic phaseBiol Targets Ther42010315323 232Tatar GizemT.K.Investigation"/>
  <result pre="231MughalT.Principal long-term adverse effects of imatinib in patients with chronic" exact="myeloid leukemia" post="in chronic phaseBiol Targets Ther42010315323 232Tatar GizemT.K.Investigation of N"/>
  <result pre="long-term adverse effects of imatinib in patients with chronic myeloid" exact="leukemia" post="in chronic phaseBiol Targets Ther42010315323 232Tatar GizemT.K.Investigation of N"/>
  <result pre="effects of imatinib in patients with chronic myeloid leukemia in" exact="chronic" post="phaseBiol Targets Ther42010315323 232Tatar GizemT.K.Investigation of N terminal domain"/>
  <result pre="protocol for early managementPharmacol Res1572020104874 237AntonyF.VashiY.MorlaS.Therapeutic potential of Nitazoxanide against" exact="Newcastle disease" post="virus: a possible modulation of host cytokinesCytokine1312020155115 238RossignolJ.F.Nitazoxanide, a"/>
  <result pre="for early managementPharmacol Res1572020104874 237AntonyF.VashiY.MorlaS.Therapeutic potential of Nitazoxanide against Newcastle" exact="disease" post="virus: a possible modulation of host cytokinesCytokine1312020155115 238RossignolJ.F.Nitazoxanide, a"/>
  <result pre="a new drug candidate for the treatment of Middle East" exact="respiratory" post="syndrome coronavirusJ Infect Public Health9201622723027095301 239ElazarM.LiuM.McKennaS.A.The anti-hepatitis C agent"/>
  <result pre="new drug candidate for the treatment of Middle East respiratory" exact="syndrome" post="coronavirusJ Infect Public Health9201622723027095301 239ElazarM.LiuM.McKennaS.A.The anti-hepatitis C agent nitazoxanide"/>
  <result pre="243RoldanE.Q.BiasiottoG.MagroP.ZanellaI.The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2" exact="infection" post="(COVID-19): a role for iron homeostasis?Pharmacol Res1582020104904 244ThomÃ©R.LopesS.C.P.CostaF.T.M.VerinaudL.Chloroquine: modes"/>
  <result pre="prophylaxis of COVID-19 patients: a scientific statement from the Indian" exact="Heart" post="Rhythm SocietyIndian Pacing Electrophysiol J20202011712032278018 246ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and hydroxychloroquine as"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov620201632194981 248TouretF.de LamballerieX.Of chloroquine and COVID-19Antiviral Res1772020104762"/>
  <result pre="in vitroCell Discov620201632194981 248TouretF.de LamballerieX.Of chloroquine and COVID-19Antiviral Res1772020104762 249DrakesmithH.PrenticeA.Viral" exact="infection" post="and iron metabolismNat Rev Microbiol6200854155218552864 250DrakesmithH.PrenticeA.M.Hepcidin and the Iron-infection"/>
  <result pre="animal virusesArch Gesamte Virusforsch361972931044335025 256KeyaertsE.VijgenL.MaesP.NeytsJ.VanRanst M.In vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun323200426426815351731 257CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A"/>
  <result pre="virusesArch Gesamte Virusforsch361972931044335025 256KeyaertsE.VijgenL.MaesP.NeytsJ.VanRanst M.In vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem Biophys Res Commun323200426426815351731 257CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic"/>
  <result pre="Gesamte Virusforsch361972931044335025 256KeyaertsE.VijgenL.MaesP.NeytsJ.VanRanst M.In vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem Biophys Res Commun323200426426815351731 257CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review"/>
  <result pre="transport of nucleocapsid proteins of enveloped RNA virusesFront Microbiol201510.3389/fmicb.2015.00553 273FriemanM.YountB.HeiseM.Severe" exact="acute" post="respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering"/>
  <result pre="of nucleocapsid proteins of enveloped RNA virusesFront Microbiol201510.3389/fmicb.2015.00553 273FriemanM.YountB.HeiseM.Severe acute" exact="respiratory" post="syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear"/>
  <result pre="nucleocapsid proteins of enveloped RNA virusesFront Microbiol201510.3389/fmicb.2015.00553 273FriemanM.YountB.HeiseM.Severe acute respiratory" exact="syndrome" post="coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import"/>
  <result pre="in vitroAntivir Res1782020104787 275KosynaF.K.NagelM.KluxenL.KraushaarK.DeppingR.The importin Î±/Î²-specific inhibitor Ivermectin affects HIF-dependent" exact="hypoxia" post="response pathwaysBiol Chem39620151357136726351913 276YavuzS.ÃœnalS.Antiviral treatment of COVID-19Turkish J Med"/>
  <result pre="Dermatol822020e221 278GonÃ§alvesA.DruceJ.D.CattonM.G.Therapeutic potential of ivermectin for COVID-19Authorea202010.22541/au.159050476.60928563 279JayawardenaR.SooriyaarachchiP.ChourdakisM.JeewandaraC.RanasingheP.Enhancing immunity in" exact="viral" post="infections, with special emphasis on COVID-19: a reviewDiabetes Metab"/>
  <result pre="novel multi-target indole-based derivatives as potent and selective inhibitors of" exact="chikungunya" post="virus replicationBioorg Med Chem25201732733727856239 285PatilS.A.PatilS.A.PatilR.Medicinal applications of (benz)imidazole- and"/>
  <result pre="Chem282020115130 289DengL.LiC.ZengQ.Arbidol combined with LPV/r versus LPV/r alone against Corona" exact="Virus Disease" post="2019: a retrospective cohort studyJ Infect812020e1e5 290ZhuZ.LuZ.XuT.Arbidol monotherapy is"/>
  <result pre="289DengL.LiC.ZengQ.Arbidol combined with LPV/r versus LPV/r alone against Corona Virus" exact="Disease" post="2019: a retrospective cohort studyJ Infect812020e1e5 290ZhuZ.LuZ.XuT.Arbidol monotherapy is"/>
  <result pre="volunteersInt J Clin Pharmacol Ther51201342343223391367 293VisserW.H.Rizatriptan vs Sumatriptan in the" exact="Acute" post="Treatment of MigraineArch Neurol.53199611328912486 294ArmijoP.R.ReginatoR.D.MaganhinC.C.AÃ§Ã£o da melatonina no tecido"/>
  <result pre="treatmentLife Sci2502020117583 296Ben-NathanD.MaestroniG.J.M.LustigS.ContiA.Protective effects of melatonin in mice infected with" exact="encephalitis" post="virusesArch Virol14019952232307710351 297SilvestriM.RossiG.A.Melatonin: its possible role in the management"/>
  <result pre="virusesArch Virol14019952232307710351 297SilvestriM.RossiG.A.Melatonin: its possible role in the management of" exact="viral" post="infections-a brief reviewItal J Pediatr3920136124090288 298ZhouY.HouY.ShenJ.Network-based drug repurposing for"/>
  <result pre="new potential synergistic treatmentLife Sci2542020117808 300TangQ.LiS.DuL.Emetine protects mice from enterovirus" exact="infection" post="by inhibiting viral translationAntiviral Res1732020104650 301YangS.XuM.LeeE.M.Emetine inhibits Zika and"/>
  <result pre="treatmentLife Sci2542020117808 300TangQ.LiS.DuL.Emetine protects mice from enterovirus infection by inhibiting" exact="viral" post="translationAntiviral Res1732020104650 301YangS.XuM.LeeE.M.Emetine inhibits Zika and Ebola virus infections"/>
  <result pre="inhibiting viral translationAntiviral Res1732020104650 301YangS.XuM.LeeE.M.Emetine inhibits Zika and Ebola virus" exact="infections" post="through two molecular mechanisms: inhibiting viral replication and decreasing"/>
  <result pre="Zika and Ebola virus infections through two molecular mechanisms: inhibiting" exact="viral" post="replication and decreasing viral entryCell Discov420183129872540 302ShenL.NiuJ.WangC.High-throughput screening and"/>
  <result pre="infections through two molecular mechanisms: inhibiting viral replication and decreasing" exact="viral" post="entryCell Discov420183129872540 302ShenL.NiuJ.WangC.High-throughput screening and identification of potent broad-spectrum"/>
  <result pre="Heal Hum Behav20201541 306KrampeH.EhrenreichH.Supervised disulfiram as adjunct to psychotherapy in" exact="alcoholism" post="treatmentCurr Pharm Des1620102076209020482514 307BanysP.The clinical use of disulfiram (AntabuseÂ®):"/>
  <result pre="vitro growth of methicillin-resistant staphylococcus aureusAntimicrob Agents Chemother3519917857872069390 309HamblinK.A.Flick-SmithH.BarnesK.B.Disulfiram, an" exact="alcohol dependence" post="therapy, can inhibit the in vitro growth of Francisella"/>
  <result pre="lamblia carbamate kinase by disulfiramJ Biol Chem2892014105021050924558036 311XuY.ZhouQ.FengX.Disulfiram/copper markedly induced" exact="myeloma" post="cell apoptosis through activation of JNK and intrinsic and"/>
  <result pre="direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in" exact="brain tumor" post="cells and mouse brain and markedly increases the alkylating"/>
  <result pre="and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain" exact="tumor" post="cells and mouse brain and markedly increases the alkylating"/>
  <result pre="human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse" exact="brain" post="and markedly increases the alkylating DNA damageCarcinogenesis35201469270224193513 313LinM.H.MosesD.C.HsiehC.H.Disulfiram can"/>
  <result pre="novel coronavirus (2019-nCoV): a systematic reviewJ Clin Med92020623 322BeigelJ.H.NamH.H.AdamsP.L.Advances in" exact="respiratory" post="virus therapeutics â€&quot; a meeting report from the 6th"/>
  <result pre="antiviral group conferenceAntiviral Res1672019456730974127 323CockrellA.S.YountB.L.ScobeyT.A mouse model for MERS coronavirus-induced" exact="acute" post="respiratory distress syndromeNat Microbiol2201716226 324CoughlinM.M.PrabhakarB.S.Neutralizing human monoclonal antibodies to"/>
  <result pre="group conferenceAntiviral Res1672019456730974127 323CockrellA.S.YountB.L.ScobeyT.A mouse model for MERS coronavirus-induced acute" exact="respiratory" post="distress syndromeNat Microbiol2201716226 324CoughlinM.M.PrabhakarB.S.Neutralizing human monoclonal antibodies to severe"/>
  <result pre="respiratory distress syndromeNat Microbiol2201716226 324CoughlinM.M.PrabhakarB.S.Neutralizing human monoclonal antibodies to severe" exact="acute" post="respiratory syndrome coronavirus: target, mechanism of action, and therapeutic"/>
  <result pre="distress syndromeNat Microbiol2201716226 324CoughlinM.M.PrabhakarB.S.Neutralizing human monoclonal antibodies to severe acute" exact="respiratory" post="syndrome coronavirus: target, mechanism of action, and therapeutic potentialRev"/>
  <result pre="syndromeNat Microbiol2201716226 324CoughlinM.M.PrabhakarB.S.Neutralizing human monoclonal antibodies to severe acute respiratory" exact="syndrome" post="coronavirus: target, mechanism of action, and therapeutic potentialRev Med"/>
  <result pre="Dis201120095244752456 331van GriensvenJ.EdwardsT.de LamballerieX.Evaluation of convalescent plasma for ebola virus" exact="disease" post="in GuineaN Engl J Med3742016334226735992 332Mair-JenkinsJ.Saavedra-CamposM.BaillieJ.K.The effectiveness of convalescent"/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis2112015809025030060"/>
  <result pre="effects of convalescent plasma therapy for patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a study protocolSpringerplus4201570926618098 334ShenC.WangZ.ZhaoF.Treatment of 5"/>
  <result pre="of convalescent plasma therapy for patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a study protocolSpringerplus4201570926618098 334ShenC.WangZ.ZhaoF.Treatment of 5 critically"/>
  <result pre="after SARS: strategies for controlling emerging coronavirusesNat Rev Microbiol11201383684824217413 338CavanaghD.Severe" exact="acute" post="respiratory syndrome vaccine development: experiences of vaccination against avian"/>
  <result pre="SARS: strategies for controlling emerging coronavirusesNat Rev Microbiol11201383684824217413 338CavanaghD.Severe acute" exact="respiratory" post="syndrome vaccine development: experiences of vaccination against avian infectious"/>
  <result pre="strategies for controlling emerging coronavirusesNat Rev Microbiol11201383684824217413 338CavanaghD.Severe acute respiratory" exact="syndrome" post="vaccine development: experiences of vaccination against avian infectious bronchitis"/>
  <result pre="acute respiratory syndrome vaccine development: experiences of vaccination against avian" exact="infectious" post="bronchitis coronavirusAvian Pathol32200356758214676007 339HolmesK.V.SARS coronavirus: a new challenge for"/>
  <result pre="respiratory syndrome vaccine development: experiences of vaccination against avian infectious" exact="bronchitis" post="coronavirusAvian Pathol32200356758214676007 339HolmesK.V.SARS coronavirus: a new challenge for prevention"/>
  <result pre="therapyJ Clin Invest11120031605160912782660 340WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe" exact="acute" post="respiratory syndrome coronavirusMicrobiol Mol Biol Rev69200563566416339739 341GaoQ.BaoL.MaoH.Development of an"/>
  <result pre="Clin Invest11120031605160912782660 340WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute" exact="respiratory" post="syndrome coronavirusMicrobiol Mol Biol Rev69200563566416339739 341GaoQ.BaoL.MaoH.Development of an inactivated"/>
  <result pre="Invest11120031605160912782660 340WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute respiratory" exact="syndrome" post="coronavirusMicrobiol Mol Biol Rev69200563566416339739 341GaoQ.BaoL.MaoH.Development of an inactivated vaccine"/>
 </snippets>
</snippetsTree>
